<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26735598</article-id><article-id pub-id-type="pmc">4690656</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20150070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Atrial Fibrillation, Neurocognitive Decline and Gene Expression After
Cardiopulmonary Bypass</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dalal</surname><given-names>Rahul S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sabe</surname><given-names>Ashraf A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Elmadhun</surname><given-names>Nassrene Y.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramlawi</surname><given-names>Basel</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sellke</surname><given-names>Frank W.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Cardiothoracic Surgery, Cardiovascular Research Center,
Warren Alpert Medical School of Brown University, Providence, RI, USA.</aff><aff id="aff2"><label>2</label>Methodist DeBakey Heart &#x00026; Vascular Center, Methodist Hospital,
Houston, Texas, USA.</aff><author-notes><corresp id="c1">Correspondence Address: Frank W. Sellke, 2 Dudley Street, MOC 360,
Providence, RI, USA 02905. E-mail: <email>fsellke@lifespan.org</email></corresp><fn fn-type="COI-statement"><p>No conflicts of interest exist for any of the authors.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2015</year></pub-date><volume>30</volume><issue>5</issue><fpage>520</fpage><lpage>532</lpage><history><date date-type="received"><day>02</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License</license-p></license></permissions><abstract><sec><title>OBJECTIVE</title><p> Atrial fibrillation and neurocognitive decline are common complications
after cardiopulmonary bypass. By utilizing genomic microarrays we
investigate whether gene expression is associated with postoperative atrial
fibrillation and neurocognitive decline.</p></sec><sec><title>METHODS</title><p> Twenty one cardiac surgery patients were prospectively matched and underwent
neurocognitive assessments pre-operatively and four days postoperatively.
The whole blood collected in the pre-cardiopulmonary bypass, 6 hours
after-cardiopulmonary bypass, and on the 4<sup>th</sup> postoperative day
was hybridized to Affymetrix Gene Chip U133 Plus 2.0 Microarrays. Gene
expression in patients who developed postoperative atrial fibrillation and
neurocognitive decline (n=6; POAF+NCD) was compared with gene expression in
patients with postoperative atrial fibrillation and normal cognitive
function (n=5; POAF+NORM) and patients with sinus rhythm and normal
cognitive function (n=10; SR+NORM). Regulated genes were identified using
JMP Genomics 4.0 with a false discovery rate of 0.05 and fold change of
&#x0003e;1.5 or &#x0003c;-1.5.</p></sec><sec><title>RESULTS</title><p> Eleven patients developed postoperative atrial fibrillation. Six of these
also developed neurocognitive decline. Of the 12 patients with sinus rhythm,
only 2 developed neurocognitive decline. POAF+NCD patients had unique
regulation of 17 named genes preoperatively, 60 named genes six hours after
cardiopulmonary bypass, and 34 named genes four days postoperatively
(<italic>P</italic>&#x0003c;0.05) compared with normal patients. Pathway
analysis demonstrated that these genes are involved in cell death,
inflammation, cardiac remodeling and nervous system function.</p></sec><sec><title>CONCLUSION</title><p> Patients who developed postoperative atrial fibrillation and neurocognitive
decline after cardiopulmonary bypass may have differential genomic responses
compared to normal patients and patients with only postoperative atrial
fibrillation, suggesting common pathophysiology for these conditions.
Further exploration of these genes may provide insight into the etiology and
improvements of these morbid outcomes.</p></sec></abstract><kwd-group><kwd>Atrial Fibrillation</kwd><kwd>Cardiopulmonary Bypass</kwd><kwd>Genes</kwd><kwd>Microarray Analysis</kwd></kwd-group><funding-group><award-group><funding-source>National Heart, Lung, and Blood Institute</funding-source><award-id>R01HL46716</award-id><award-id>T35HL094308</award-id></award-group><award-group><funding-source>NIH</funding-source><award-id>5T32-HL094300-03</award-id></award-group><funding-statement>Financial Support: Funding for this research was provided by the
National Heart, Lung, and Blood Institute (R01HL46716, Dr. Sellke; T35HL094308,
Dr. Dalal) and NIH Training grant 5T32-HL094300-03 (Drs. Sabe and
Elmadhun).</funding-statement></funding-group></article-meta></front><body><table-wrap id="t15" orientation="portrait" position="float"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th colspan="2" align="left" rowspan="1">
<bold>Abbreviations, acronyms &#x00026; symbols</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AF</td><td rowspan="1" colspan="1">= Atrial fibrillation</td></tr><tr><td rowspan="1" colspan="1">CABG</td><td rowspan="1" colspan="1">= Coronary artery bypass graft</td></tr><tr><td rowspan="1" colspan="1">CPB</td><td rowspan="1" colspan="1">= Cardiopulmonary bypass</td></tr><tr><td rowspan="1" colspan="1">NCD</td><td rowspan="1" colspan="1">= Neurocognitive decline</td></tr><tr><td rowspan="1" colspan="1">POAF</td><td rowspan="1" colspan="1">= Postoperative atrial fibrillation</td></tr><tr><td rowspan="1" colspan="1">SR</td><td rowspan="1" colspan="1">= Sinus rhythm</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Surgical advancements have allowed an increasingly older population to undergo
cardiac surgery and cardiopulmonary bypass (CPB) with a low mortality risk. Efforts
have therefore focused on reducing postoperative morbidity. Neurocognitive decline
(NCD, up to 80% incidence) and atrial fibrillation (AF, 20-45% incidence) remain two
of the most common complications after CPB<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Coronary artery bypass graft (CABG) guidelines by the
American College of Cardiology/American Heart Association describe two types of
neurocognitive deficits, with type 2 representing the vast
majority<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.
Type 2 deficits are global and may include confusion and intellectual and memory
decline without a known focal lesion and may significantly impair patients' quality
of life. The etiology of these deficits is likely related to multiple factors
including age, procedure, CPB time, hypoxia, and inflammation<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Up to 30% of type 2
deficits persist for at least one year and early NCD appears to predict long-term
deficits<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>Like NCD, the high incidence of postoperative AF (POAF) has persisted. POAF generally
occurs by postoperative day four and may precipitate heart failure and
cerebrovascular emboli<sup>[<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>.
Because of increased hospital stay and readmissions, it is estimated that healthcare
costs for patients who develop POAF are $10,000 higher than for those who do
not<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.
Though several factors have been correlated with POAF after cardiac surgery, our
inability to eliminate its incidence may be related to unknown pathophysiologic
mechanisms. Studies have proposed that oxidation and inflammation after CPB induce
cardiomyocyte damage and predispose to the development of atrial
arrhythmias<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Experiments in a canine model of rapid atrial pacing
demonstrated that statins, which are known for their anti-inflammatory and
anti-oxidant properties, reduced shortening of the atrial effective refractory
period and thus POAF susceptibility<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. In a case-control study, our group previously
demonstrated that patients with POAF had elevated serum peroxide levels, excess
myocardial oxidation, and an increased oxidative genomic response compared with
patients in sinus rhythm (SR)<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>While these complications have been studied independently, prior research suggests an
association between POAF and neurologic abnormalities<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. In a prospective
observational study, Stanley et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> found significantly more cognitive deficits in
patients who developed POAF, which was also associated with worse cognitive
functioning six weeks after surgery. While it is thought that the paroxysmal nature
of POAF, embolization, and decreased cardiac output increase risk for neurologic
dysfunction, it remains unknown if there are common pathways by which both NCD and
POAF arise.</p><p>High-throughput microarray provides a practical approach to investigate genomic
changes and disease development. Microarrays can screen the entire human genome for
regulated genes and bring light to the underlying pathways that may promote
morbidities like NCD and POAF. We previously utilized microarray to demonstrate
increased expression of genes involved with inflammation and neurologic dysfunction
in patients who developed NCD after CPB compared to patients without NCD
(NORM)<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.
We now examine gene expression changes in patients who develop both POAF and NCD
(POAF+NCD) compared to patients spared of these complications (SR+NORM) and those
who develop POAF alone (POAF+NORM). To further investigate the underlying
pathophysiology of these disease processes we utilize modern microarray and
bioinformatics techniques to identify genes that may be associated with the combined
incidence of these complications.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patient Enrollment and Matching</title><p>We performed a single-institution, prospective cohort study approved by the Beth
Israel Deaconess Medical Center Institutional Review Board/Committee on Clinical
Investigations in Boston, MA. Forty-two consecutive patients were scheduled for
urgent or elective primary CABG, valve replacement (mitral or aortic), or a
combination of both requiring CPB. All study participants were provided informed
written consent for surgical procedures and blood collection for this
investigation. Patients with pre-operative documented AF, high-grade carotid
stenosis, known calcified aortas, recent cerebrovascular accident, severe
neurologic deficits, serum creatinine&#x0003e;2.0 mg/dL, and hepatic cirrhosis were
excluded. Subjects undergoing aortic root/arch procedures, on antiarrhythmic
medications, or unable to complete neurocognitive assessments were also
excluded.</p><p>POAF was defined as sustained AF confirmed by electrocardiogram before
postoperative day five that required anticoagulation or cardioversion. Of the 42
subjects enrolled, only the subset that developed both POAF and NCD was
prospectively matched with selected SR+NORM and POAF+NORM patients based on
pre-operative baseline characteristics (i.e. sex, age, hypercholesterolemia,
hypertension, diabetes mellitus, white blood cell count, &#x003b2;-blocker use),
intraoperative characteristics (i.e. CPB and aortic cross-clamp time, cardiotomy
suction and antifibrinolytic use, procedure type), and postoperative
characteristics (i.e. &#x003b2;-blocker use and time to extubation). Subsequent
serologic and molecular studies were performed in a blinded fashion.</p></sec><sec><title>Surgical Technique</title><p>We followed our institution's conventional operative approach regarding general
anesthesia induction, midline sternotomy, systemic heparinization, CPB, and
invasive monitoring as previously described<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p></sec><sec><title>Neurocognitive Assessment</title><p>Patients underwent neurocognitive assessments performed by trained, blinded
psychometricians between 1 and 10 days pre-operatively, on postoperative day 4,
and in the 3<sup>rd</sup> month of the postoperative period. Patients were also
evaluated for depression using the Geriatric Depression Scale. Memory,
attention, language, global cognition, and executive functioning were assessed
using 8 validated tools:</p><p>The Hopkins Verbal Learning Test measured verbal learning, recall, and retention
by assessing the maximum number of items learned, the number of items recalled
after 20 minutes divided by the maximum number learned, and the number of items
correctly named from a list. Working memory and attention span were measured
using Digit Span. Attention shifting ability was assessed by recording the time
needed to complete Trailmaking A and B. Confrontational naming was measured
using the Boston Naming Test. Fluency was evaluated by requiring patients to
generate words beginning with a specific letter (phonemic fluency) or in a
category (semantic fluency). The Visual Search and Acuity Test and Stroop
Color-Word Inference Test measured visuospatial abilities and executive
function. Premorbid intelligence was measured using the Wechsler Test of Adult
Reading. In accordance with the "Statement of consensus on assessment of
neurobehavioral outcomes after cardiac surgery," NCD was defined as a 1-standard
deviation deficit from baseline on 25% of tasks<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p></sec><sec><title>Blood Collection and Microarray Processing</title><p>Blood samples were drawn from patients via central venous catheter
pre-operatively immediately after anesthesia induction (pre-CPB), 6 hours
postoperatively in the intensive care unit (post-CPB), and on postoperative day
four (4D). Whole blood was drawn into PAXgene tubes (QIAGEN Inc, Valencia, Ca)
for extraction and mRNA stabilization per the manufacturer's instructions.</p><p>RNA extraction and purification from whole blood, cDNA synthesis, and generation
of biotin-labeled cRNA were performed by the Beth Israel Deaconess Medical
Center Proteomics Core according to prior protocols<sup>[<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>. All cRNA samples were hybridized to
Affymetrix GeneChip HG-U133 Plus 2.0 microarrays (Affymetric INc, Santa Clara,
Ca). Chips were scanned using the HP G2500A ChipScanner (Affymetrix) and dChip
software (Wong et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, Boston, MA) was used for quality control analysis
and signal measurement. No outliers were identified and all samples underwent
subsequent pathway analysis.</p></sec><sec><title>Gene Expression and Pathway Analysis</title><p>Raw microarray data underwent gene expression analysis using JMP Genomics 4.0
(SAS, Cary, NC) for normalization, quality control, and statistical analysis.
The Robust Multichip Average method normalized and compared composite chip data.
Gene expression in Pre-CPB, Post-CPB, and 4D blood samples for POAF+NCD patients
were compared to corresponding samples from SR+NORM and POAF+NORM using one-way
ANOVA. A post-hoc false discovery rate algorithm with alpha of 0.05 minimized
false positive results. Significantly, regulated genes met two criteria: 1) -log
(<italic>P</italic>-value) exceeding the threshold calculated by JMP
Genomics for each comparison and 2) fold change in gene expression &#x0003e;1.5 or
&#x0003c;-1.5 between groups. A 1.5-fold change cutoff was chosen here and in a prior
study of this patient population to reduce background noise while not limiting
results to the most labile genes<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Significantly regulated genes were uploaded into
Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City, CA) to
generate top canonical pathways regulated by the selected genes.</p></sec><sec><title>Real-time PCR</title><p>Gene expression analysis of whole blood-derived mRNA with Affymetrix GeneChip
HG-U133 Plus 2.0 microarrays was validated previously by real-time
PCR<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Patient Characteristics</title><p>Patients with POAF+NCD (n=6) were prospectively matched with SR+NORM (n=10) and
POAF+NORM (n=5). <xref ref-type="table" rid="t1">Table 1</xref> lists
well-matched baseline characteristics of these subjects and shows no significant
differences in race, sex, age, and co-morbidities as calculated by one-way
ANOVA. Patients underwent similar intraoperative courses with regard to
anesthesia, CPB technique, temperature, and perioperative monitoring. There were
no differences in other postoperative complications, such as focal neurologic
deficits or cerebrovascular events in patients with POAF compared to SR during
the study period. Of 11 total POAF patients, 6 developed NCD (54.5%), and of 12
SR patients, only 2 developed NCD (16.7%). After three months, all but one
patient returned regained normal cognitive function<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics for matching of patients who developed POAF and NCD with
controls.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">A POAF+NCD (n=6)</th><th align="center" rowspan="1" colspan="1">B SR+NORM (n=10)</th><th align="center" rowspan="1" colspan="1">C POAF+NORM (n=5)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">Pre-operative data</td></tr><tr><td rowspan="1" colspan="1">Age (y)<xref ref-type="table-fn" rid="TFN01">a</xref></td><td align="center" rowspan="1" colspan="1">66.5&#x000b1;7.4</td><td align="center" rowspan="1" colspan="1">69.2&#x000b1;7.1</td><td align="center" rowspan="1" colspan="1">73.4&#x000b1;5.8</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td rowspan="1" colspan="1">Sex (% male)</td><td align="center" rowspan="1" colspan="1">83.3 (5/6)</td><td align="center" rowspan="1" colspan="1">100<bold>
(</bold>10<bold>/</bold>10<bold>)</bold></td><td align="center" rowspan="1" colspan="1">80.0 (4/5)</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td rowspan="1" colspan="1">Hypertension (% of group)</td><td align="center" rowspan="1" colspan="1">83.3 (5/6)</td><td align="center" rowspan="1" colspan="1">70.0 (7/10)</td><td align="center" rowspan="1" colspan="1">40.0 (2/5)</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td rowspan="1" colspan="1">Hypercholesterolemia (% of group)</td><td align="center" rowspan="1" colspan="1">50.0 (3/6)</td><td align="center" rowspan="1" colspan="1">50.0 (5/10)</td><td align="center" rowspan="1" colspan="1">20.0 (1/5)</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus (% of group)</td><td align="center" rowspan="1" colspan="1">50.0 (3/6)</td><td align="center" rowspan="1" colspan="1">30.0 (3/10)</td><td align="center" rowspan="1" colspan="1">40.0 (2/5)</td><td align="center" rowspan="1" colspan="1">0.76</td></tr><tr><td rowspan="1" colspan="1">Leukocytes (103 cells/&#x000b5;L)<xref ref-type="table-fn" rid="TFN01">a</xref></td><td align="center" rowspan="1" colspan="1">7.4&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">7.2&#x000b1;2.0</td><td align="center" rowspan="1" colspan="1">10.3&#x000b1;2.9</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td rowspan="1" colspan="1">Hematocrit (%)</td><td align="center" rowspan="1" colspan="1">35.6&#x000b1;4.3</td><td align="center" rowspan="1" colspan="1">34.5&#x000b1;4.0</td><td align="center" rowspan="1" colspan="1">37.7&#x000b1;7.6</td><td align="center" rowspan="1" colspan="1">0.53</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">Glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">193&#x000b1;131</td><td align="center" rowspan="1" colspan="1">163&#x000b1;68</td><td align="center" rowspan="1" colspan="1">118&#x000b1;38</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td colspan="5" align="left" rowspan="1">Intraoperative data</td></tr><tr><td rowspan="1" colspan="1">Procedure (% CABG)</td><td align="center" rowspan="1" colspan="1">83.3 (5/6)</td><td align="center" rowspan="1" colspan="1">70.0 (7/10)</td><td align="center" rowspan="1" colspan="1">80.0 (4/5)</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td rowspan="1" colspan="1">CPB time (min)<xref ref-type="table-fn" rid="TFN01">a</xref></td><td align="center" rowspan="1" colspan="1">78.3&#x000b1;32.6</td><td align="center" rowspan="1" colspan="1">78.9&#x000b1;26.3</td><td align="center" rowspan="1" colspan="1">70.6&#x000b1;20.1</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">Cross-clamp time (min)<xref ref-type="table-fn" rid="TFN01">a</xref></td><td align="center" rowspan="1" colspan="1">57.7&#x000b1;23.9</td><td align="center" rowspan="1" colspan="1">63.0&#x000b1;21.0</td><td align="center" rowspan="1" colspan="1">46.4&#x000b1;21.3</td><td align="center" rowspan="1" colspan="1">0.40</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><label>a</label><p><italic>Values are mean</italic> &#x000b1; <italic>SD</italic></p></fn><p>CABG=coronary artery bypass graft; CPB=cardiopulmonary bypass;
POAF=post-operative atrial fibrillation; SR=sinus rhythm</p></table-wrap-foot></table-wrap></sec><sec><title>Gene Expression and Confirmation</title><p>We previously published comprehensive gene expression databases of patients with
POAF or SR before and after CPB as well as patients with and without NCD after
CPB, including unsupervised hierarchical sample clustering, and confirmation of
microarray gene-expression data with real-time PCR<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>. Our described microarray GeneChip
identified 54,675 transcripts. Complete lists of genes regulated in the
comparisons of POAF+NCD vs. SR+NORM or POAF+NORM are provided in <xref ref-type="table" rid="t2">Tables 2</xref> to <xref ref-type="table" rid="t7">7</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Pre-CPB gene expression in patients with POAF+NCD compared with SR+NORM -
complete list.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ADM2</td><td rowspan="1" colspan="1">adrenomedullin 2</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">1.12E-05</td></tr><tr><td rowspan="1" colspan="1">CA11</td><td rowspan="1" colspan="1">carbonic anhydrase XI</td><td align="center" rowspan="1" colspan="1">1.58</td><td align="center" rowspan="1" colspan="1">4.47E-05</td></tr><tr><td rowspan="1" colspan="1">CD101</td><td rowspan="1" colspan="1">CD101 molecule</td><td align="center" rowspan="1" colspan="1">2.19</td><td align="center" rowspan="1" colspan="1">1.15E-04</td></tr><tr><td rowspan="1" colspan="1">COMTD1</td><td rowspan="1" colspan="1">catechol-O-methyltransferase domain containing 1</td><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">2.29E-05</td></tr><tr><td rowspan="1" colspan="1">GAS6-AS1</td><td rowspan="1" colspan="1">GAS6 antisense RNA 1</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">5.37E-05</td></tr><tr><td rowspan="1" colspan="1">KCNIP3</td><td rowspan="1" colspan="1">Kv channel interacting protein 3, calsenilin</td><td align="center" rowspan="1" colspan="1">1.56</td><td align="center" rowspan="1" colspan="1">2.51E-22</td></tr><tr><td rowspan="1" colspan="1">MCF2L</td><td rowspan="1" colspan="1">MCF.2 cell line derived transforming sequence-like</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">1.00E-04</td></tr><tr><td rowspan="1" colspan="1">MECR</td><td rowspan="1" colspan="1">mitochondrial trans-2-enoyl-CoA reductase</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">2.19E-07</td></tr><tr><td rowspan="1" colspan="1">MMP11</td><td rowspan="1" colspan="1">matrix metallopeptidase 11 (stromelysin 3)</td><td align="center" rowspan="1" colspan="1">1.71</td><td align="center" rowspan="1" colspan="1">5.01E-15</td></tr><tr><td rowspan="1" colspan="1">NUTM2F/NUTM2G</td><td rowspan="1" colspan="1">NUT family member 2G</td><td align="center" rowspan="1" colspan="1">1.89</td><td align="center" rowspan="1" colspan="1">6.31E-13</td></tr><tr><td rowspan="1" colspan="1">PHF20</td><td rowspan="1" colspan="1">PHD finger protein 20</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">1.78E-05</td></tr><tr><td rowspan="1" colspan="1">PYCR1</td><td rowspan="1" colspan="1">pyrroline-5-carboxylate reductase 1</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">5.37E-05</td></tr><tr><td rowspan="1" colspan="1">RGS12</td><td rowspan="1" colspan="1">regulator of G-protein signaling 12</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">9.77E-06</td></tr><tr><td rowspan="1" colspan="1">TOM1L2</td><td rowspan="1" colspan="1">target of myb1-like 2 (chicken)</td><td align="center" rowspan="1" colspan="1">1.60</td><td align="center" rowspan="1" colspan="1">1.15E-04</td></tr><tr><td rowspan="1" colspan="1">VGLL1</td><td rowspan="1" colspan="1">vestigial like 1 (Drosophila)</td><td align="center" rowspan="1" colspan="1">1.87</td><td align="center" rowspan="1" colspan="1">3.02E-07</td></tr><tr><td rowspan="1" colspan="1">WIZ</td><td rowspan="1" colspan="1">widely interspaced zinc finger motifs</td><td align="center" rowspan="1" colspan="1">1.83</td><td align="center" rowspan="1" colspan="1">8.91E-10</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">ZBED5</td><td rowspan="1" colspan="1">zinc finger, BED-type containing 5</td><td align="center" rowspan="1" colspan="1">1.63</td><td align="center" rowspan="1" colspan="1">1.07E-04</td></tr></tbody></table><table-wrap-foot><fn id="TFN03"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t7" orientation="portrait" position="float"><label>Table 7</label><caption><p>4D gene expression in patients with POAF+NCD compared with POAF+NORM -
complete list.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ACSL6</td><td rowspan="1" colspan="1">acyl-CoA synthetase long-chain family member 6</td><td align="center" rowspan="1" colspan="1">1.62</td><td align="center" rowspan="1" colspan="1">8.13E-06</td></tr><tr><td rowspan="1" colspan="1">ADAMTS6</td><td rowspan="1" colspan="1">ADAM metallopeptidase with thrombospondin type 1 motif, 6</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">4.37E-05</td></tr><tr><td rowspan="1" colspan="1">ADRBK2</td><td rowspan="1" colspan="1">adrenergic, beta, receptor kinase 2</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">1.29E-09</td></tr><tr><td rowspan="1" colspan="1">AGPAT6</td><td rowspan="1" colspan="1">1-acylglycerol-3-phosphate O-acyltransferase 6</td><td align="center" rowspan="1" colspan="1">1.63</td><td align="center" rowspan="1" colspan="1">1.58E-12</td></tr><tr><td rowspan="1" colspan="1">BCL2L1</td><td rowspan="1" colspan="1">BCL2-like 1</td><td align="center" rowspan="1" colspan="1">2.75</td><td align="center" rowspan="1" colspan="1">3.09E-06</td></tr><tr><td rowspan="1" colspan="1">C20orf203</td><td rowspan="1" colspan="1">chromosome 20 open reading frame 203</td><td align="center" rowspan="1" colspan="1">0.31</td><td align="center" rowspan="1" colspan="1">3.16E-14</td></tr><tr><td rowspan="1" colspan="1">CASC7</td><td rowspan="1" colspan="1">cancer susceptibility candidate 7 (non-protein coding)</td><td align="center" rowspan="1" colspan="1">1.75</td><td align="center" rowspan="1" colspan="1">1.05E-10</td></tr><tr><td rowspan="1" colspan="1">CBL</td><td rowspan="1" colspan="1">Cbl proto-oncogene, E3 ubiquitin protein ligase</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">3.02E-10</td></tr><tr><td rowspan="1" colspan="1">CDC42BPA</td><td rowspan="1" colspan="1">CDC42 binding protein kinase alpha (DMPK-like)</td><td align="center" rowspan="1" colspan="1">2.24</td><td align="center" rowspan="1" colspan="1">2.24E-10</td></tr><tr><td rowspan="1" colspan="1">CDCA7</td><td rowspan="1" colspan="1">cell division cycle associated 7</td><td align="center" rowspan="1" colspan="1">1.88</td><td align="center" rowspan="1" colspan="1">1.70E-09</td></tr><tr><td rowspan="1" colspan="1">CHD2</td><td rowspan="1" colspan="1">chromodomain helicase DNA binding protein 2</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">2.40E-05</td></tr><tr><td rowspan="1" colspan="1">CHERP</td><td rowspan="1" colspan="1">calcium homeostasis endoplasmic reticulum protein</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">8.91E-07</td></tr><tr><td rowspan="1" colspan="1">CLIC2</td><td rowspan="1" colspan="1">chloride intracellular channel 2</td><td align="center" rowspan="1" colspan="1">2.08</td><td align="center" rowspan="1" colspan="1">5.01E-27</td></tr><tr><td rowspan="1" colspan="1">DCAF15</td><td rowspan="1" colspan="1">DDB1 and CUL4 associated factor 15</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">5.89E-05</td></tr><tr><td rowspan="1" colspan="1">DDX17</td><td rowspan="1" colspan="1">DEAD (Asp-Glu-Ala-Asp) box helicase 17</td><td align="center" rowspan="1" colspan="1">6.55</td><td align="center" rowspan="1" colspan="1">2.29E-06</td></tr><tr><td rowspan="1" colspan="1">DLD</td><td rowspan="1" colspan="1">dihydrolipoamide dehydrogenase</td><td align="center" rowspan="1" colspan="1">1.89</td><td align="center" rowspan="1" colspan="1">2.51E-25</td></tr><tr><td rowspan="1" colspan="1">DOCK1</td><td rowspan="1" colspan="1">dedicator of cytokinesis 1</td><td align="center" rowspan="1" colspan="1">2.10</td><td align="center" rowspan="1" colspan="1">1.00E-10</td></tr><tr><td rowspan="1" colspan="1">EPB41L4B</td><td rowspan="1" colspan="1">erythrocyte membrane protein band 4.1 like 4B</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">7.94E-49</td></tr><tr><td rowspan="1" colspan="1">FRMD8</td><td rowspan="1" colspan="1">FERM domain containing 8</td><td align="center" rowspan="1" colspan="1">3.33</td><td align="center" rowspan="1" colspan="1">2.51E-17</td></tr><tr><td rowspan="1" colspan="1">GLCCI1</td><td rowspan="1" colspan="1">glucocorticoid induced transcript 1</td><td align="center" rowspan="1" colspan="1">2.43</td><td align="center" rowspan="1" colspan="1">1.29E-08</td></tr><tr><td rowspan="1" colspan="1">GRB10</td><td rowspan="1" colspan="1">growth factor receptor-bound protein 10</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">7.94E-14</td></tr><tr><td rowspan="1" colspan="1">HEMGN</td><td rowspan="1" colspan="1">hemogen</td><td align="center" rowspan="1" colspan="1">2.75</td><td align="center" rowspan="1" colspan="1">1.45E-09</td></tr><tr><td rowspan="1" colspan="1">IDE</td><td rowspan="1" colspan="1">insulin-degrading enzyme</td><td align="center" rowspan="1" colspan="1">1.56</td><td align="center" rowspan="1" colspan="1">2.82E-05</td></tr><tr><td rowspan="1" colspan="1">L1CAM</td><td rowspan="1" colspan="1">L1 cell adhesion molecule</td><td align="center" rowspan="1" colspan="1">1.60</td><td align="center" rowspan="1" colspan="1">1.05E-05</td></tr><tr><td rowspan="1" colspan="1">LOC100505812</td><td rowspan="1" colspan="1">uncharacterized LOC100505812</td><td align="center" rowspan="1" colspan="1">0.55</td><td align="center" rowspan="1" colspan="1">5.01E-11</td></tr><tr><td rowspan="1" colspan="1">MED1</td><td rowspan="1" colspan="1">mediator complex subunit 1</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">6.03E-06</td></tr><tr><td rowspan="1" colspan="1">MMD</td><td rowspan="1" colspan="1">monocyte to macrophage differentiation-associated</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">3.09E-09</td></tr><tr><td rowspan="1" colspan="1">MS4A6A</td><td rowspan="1" colspan="1">membrane-spanning 4-domains, subfamily A, member 6A</td><td align="center" rowspan="1" colspan="1">2.48</td><td align="center" rowspan="1" colspan="1">7.94E-14</td></tr><tr><td rowspan="1" colspan="1">NCR1</td><td rowspan="1" colspan="1">natural cytotoxicity triggering receptor 1</td><td align="center" rowspan="1" colspan="1">2.45</td><td align="center" rowspan="1" colspan="1">1.07E-04</td></tr><tr><td rowspan="1" colspan="1">NEDD4L</td><td rowspan="1" colspan="1">neural precursor cell expressed, developmentally down-regulated
4-like, E3 ubiquitin protein ligase</td><td align="center" rowspan="1" colspan="1">1.57</td><td align="center" rowspan="1" colspan="1">2.04E-07</td></tr><tr><td rowspan="1" colspan="1">ODF4</td><td rowspan="1" colspan="1">outer dense fiber of sperm tails 4</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">1.00E-09</td></tr><tr><td rowspan="1" colspan="1">OSBPL11</td><td rowspan="1" colspan="1">oxysterol binding protein-like 11</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">2.51E-26</td></tr><tr><td rowspan="1" colspan="1">PRDM2</td><td rowspan="1" colspan="1">PR domain containing 2, with ZNF domain</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">3.09E-05</td></tr><tr><td rowspan="1" colspan="1">PTAR1</td><td rowspan="1" colspan="1">protein prenyltransferase alpha subunit repeat containing 1</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">8.13E-06</td></tr><tr><td rowspan="1" colspan="1">PTPLB</td><td rowspan="1" colspan="1">protein tyrosine phosphatase-like (proline instead of catalytic
arginine), member b</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">8.71E-05</td></tr><tr><td rowspan="1" colspan="1">PTPN9</td><td rowspan="1" colspan="1">protein tyrosine phosphatase, non-receptor type 9</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">4.68E-05</td></tr><tr><td rowspan="1" colspan="1">RAB32</td><td rowspan="1" colspan="1">RAB32, member RAS oncogene family</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">1.15E-04</td></tr><tr><td rowspan="1" colspan="1">RASSF1</td><td rowspan="1" colspan="1">Ras association (RalGDS/AF-6) domain family member 1</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">3.24E-06</td></tr><tr><td rowspan="1" colspan="1">RBM12B</td><td rowspan="1" colspan="1">RNA binding motif protein 12B</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">3.98E-11</td></tr><tr><td rowspan="1" colspan="1">REEP1</td><td rowspan="1" colspan="1">receptor accessory protein 1</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">2.45E-07</td></tr><tr><td rowspan="1" colspan="1">RPL10</td><td rowspan="1" colspan="1">ribosomal protein L10</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">7.08E-09</td></tr><tr><td rowspan="1" colspan="1">SERPINE1</td><td rowspan="1" colspan="1">serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">4.79E-05</td></tr><tr><td rowspan="1" colspan="1">SGOL1</td><td rowspan="1" colspan="1">shugoshin-like 1 (S. pombe)</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">2.69E-06</td></tr><tr><td rowspan="1" colspan="1">SLC22A7</td><td rowspan="1" colspan="1">solute carrier family 22 (organic anion transporter), member
7</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">7.94E-12</td></tr><tr><td rowspan="1" colspan="1">SLC5A4</td><td rowspan="1" colspan="1">solute carrier family 5 (low affinity glucose cotransporter),
member 4</td><td align="center" rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">3.02E-05</td></tr><tr><td rowspan="1" colspan="1">SMC3</td><td rowspan="1" colspan="1">structural maintenance of chromosomes 3</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">3.16E-27</td></tr><tr><td rowspan="1" colspan="1">TCF4</td><td rowspan="1" colspan="1">transcription factor 4</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">1.38E-07</td></tr><tr><td rowspan="1" colspan="1">UBE2H</td><td rowspan="1" colspan="1">ubiquitin-conjugating enzyme E2H</td><td align="center" rowspan="1" colspan="1">2.64</td><td align="center" rowspan="1" colspan="1">1.58E-06</td></tr><tr><td rowspan="1" colspan="1">VPS37A</td><td rowspan="1" colspan="1">vacuolar protein sorting 37 homolog A (S. cerevisiae)</td><td align="center" rowspan="1" colspan="1">1.71</td><td align="center" rowspan="1" colspan="1">1.10E-04</td></tr><tr><td rowspan="1" colspan="1">WHAMMP2</td><td rowspan="1" colspan="1">WAS protein homolog associated with actin, golgi membranes and
microtubules pseudogene 2</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">5.75E-08</td></tr><tr><td rowspan="1" colspan="1">YOD1</td><td rowspan="1" colspan="1">YOD1 deubiquitinase</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">3.47E-05</td></tr><tr><td rowspan="1" colspan="1">ZEB1</td><td rowspan="1" colspan="1">zinc finger E-box binding homeobox 1</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">1.26E-04</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">ZNF395</td><td rowspan="1" colspan="1">zinc finger protein 395</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">1.10E-06</td></tr></tbody></table><table-wrap-foot><fn id="TFN08"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Gene Expression and Pathway Analysis in POAF+NCD vs. SR+NORM</title><p>
<xref ref-type="fig" rid="f1">Figure 1</xref> shows the distribution of
regulated genes by fold-change for each time point in this comparison. Pre-CPB,
19 genes were significantly regulated in the POAF+NCD group compared to NORM+SR,
of which 17 were named. Notably, 16 of these 17 genes were up-regulated, while 1
was down-regulated. Pathway analysis used to group genes by potential
pathophysiologic functions demonstrated that these genes are related to
cardiovascular disease, nervous system function, and cell death, as described in
<xref ref-type="table" rid="t8">Table 8</xref>. Post-CPB, the number of
genes increased to 65, of which 60 were named. All 60 were up-regulated, and
while distinct from those regulated pre-operatively, pathway analysis
demonstrated that many of these genes are associated with cardiovascular disease
and remodeling, inflammation, and nervous system disorders, as seen in <xref ref-type="table" rid="t9">Table 9</xref>. At 4D, the number of genes
decreased to 41, of which 34 were named. Of these, 30 were up-regulated while 4
were down-regulated. Several genes, as listed in <xref ref-type="table" rid="t10">Table 10</xref>, are similarly involved with cardiovascular
disease, nervous system function, inflammation, and protein degradation.</p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Distribution of genes regulated for POAF+NCD <italic>vs.</italic>
SR+NORM.</p></caption><graphic xlink:href="rbccv-30-05-0520-g01"/></fig><table-wrap id="t8" orientation="portrait" position="float"><label>Table 8</label><caption><p>Pre-CPB Gene Expression in Patients with POAF and NCD compared with SR
and NORM - selected genes grouped by poten-tial pathophysiologic
function.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cardiovascular disease</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">ADM2</td><td rowspan="1" colspan="1">adrenomedullin-2</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">1.00E-04</td></tr><tr><td colspan="4" rowspan="1">Nervous system function</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">KCNIP3</td><td rowspan="1" colspan="1">Kv channel interacting protein 3, calsenilin</td><td align="center" rowspan="1" colspan="1">1.56</td><td align="center" rowspan="1" colspan="1">2.51E-22</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cell death and survival</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">MMP11</td><td rowspan="1" colspan="1">matrix metallopeptidase 11 (stromelysin 3)</td><td align="center" rowspan="1" colspan="1">1.71</td><td align="center" rowspan="1" colspan="1">5.01E-15</td></tr></tbody></table><table-wrap-foot><fn id="TFN09"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t9" orientation="portrait" position="float"><label>Table 9</label><caption><p>Post-CPB gene expression in patients with POAF and NCD compared with SR
and NORM - selected genes grouped by poten-tial pathophysiologic
function.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cardiovascular disease</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">BMX</td><td rowspan="1" colspan="1">BMX non-receptor tyrosine kinase</td><td align="center" rowspan="1" colspan="1">7.32</td><td align="center" rowspan="1" colspan="1">1.00E-14</td></tr><tr><td rowspan="1" colspan="1">EPAS1</td><td rowspan="1" colspan="1">endothelial PAS domain protein 1</td><td align="center" rowspan="1" colspan="1">2.43</td><td align="center" rowspan="1" colspan="1">6.17E-05</td></tr><tr><td rowspan="1" colspan="1">HGF</td><td rowspan="1" colspan="1">hepatocyte growth factor (hepapoietin A; scatter factor)</td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">3.47E-05</td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td rowspan="1" colspan="1">MAPK14</td><td rowspan="1" colspan="1">mitogen-activated protein kinase 14</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">2.51E-28</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Nervous system function</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">KIDINS220</td><td rowspan="1" colspan="1">kinase D-interacting substrate, 220kDa</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">7.08E-06</td></tr><tr><td rowspan="1" colspan="1">SYNE1</td><td rowspan="1" colspan="1">spectrin repeat containing, nuclear envelope 1</td><td align="center" rowspan="1" colspan="1">3.11</td><td align="center" rowspan="1" colspan="1">3.09E-06</td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td rowspan="1" colspan="1">YKT6</td><td rowspan="1" colspan="1">YKT6 v-SNARE homolog (S. cerevisiae)</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">3.39E-05</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Inflammation</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td rowspan="1" colspan="1">CREBBP</td><td rowspan="1" colspan="1">CREB binding protein</td><td align="center" rowspan="1" colspan="1">1.83</td><td align="center" rowspan="1" colspan="1">1.29E-06</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Pyschological disorders</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom-style:solid;border-bottom-width:thick"><td rowspan="1" colspan="1">TMLHE</td><td rowspan="1" colspan="1">trimethyllysine hydroxylase, epsilon</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">3.47E-05</td></tr></tbody></table><table-wrap-foot><fn id="TFN10"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t10" orientation="portrait" position="float"><label>Table 10</label><caption><p>4D Gene expression in patients with AF and NCD compared with SR and NORM
&#x02013; selected genes grouped by potential pathophysiologic function.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cardiovascular disease</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">BCL2L1</td><td rowspan="1" colspan="1">BCL2-like 1</td><td align="center" rowspan="1" colspan="1">3.17</td><td align="center" rowspan="1" colspan="1">1.58E-13</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">PRKAA2</td><td rowspan="1" colspan="1">protein kinase, AMP-activated, alpha 2 catalytic subunit</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">5.37E-05</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Nervous system function</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">IDE</td><td rowspan="1" colspan="1">insulin-degrading enzyme</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">6.61E-06</td></tr><tr><td rowspan="1" colspan="1">CDC42BPA</td><td rowspan="1" colspan="1">CDC42 binding protein kinase alpha (DMPK-like)</td><td align="center" rowspan="1" colspan="1">1.94</td><td align="center" rowspan="1" colspan="1">1.86E-08</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">PLXNB1</td><td rowspan="1" colspan="1">plexin B1</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">1.00E-15</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Inflammation</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">NCR1</td><td rowspan="1" colspan="1">natural cytotoxicity triggering receptor 1</td><td align="center" rowspan="1" colspan="1">1.90</td><td align="center" rowspan="1" colspan="1">2.57E-05</td></tr><tr><td rowspan="1" colspan="1">DOCK1</td><td rowspan="1" colspan="1">dedicator of cytokinesis 1</td><td align="center" rowspan="1" colspan="1">2.09</td><td align="center" rowspan="1" colspan="1">6.31E-50</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">SMC3</td><td rowspan="1" colspan="1">structural maintenance of chromosomes 3</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">4.47E-06</td></tr><tr style="border-right-style:hidden"><td rowspan="1" colspan="1">Protein degradation</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">DLD</td><td rowspan="1" colspan="1">dihydrolipoamide dehydrogenase</td><td align="center" rowspan="1" colspan="1">2.13</td><td align="center" rowspan="1" colspan="1">3.16E-14</td></tr><tr><td rowspan="1" colspan="1">NEDD4L</td><td rowspan="1" colspan="1">neural precursor cell expressed, developmentally down-regulated
4-like, E3 ubiquitin protein ligase</td><td align="center" rowspan="1" colspan="1">1.60</td><td align="center" rowspan="1" colspan="1">6.31E-11</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">UBE2H</td><td rowspan="1" colspan="1">ubiquitin-conjugating enzyme E2H</td><td align="center" rowspan="1" colspan="1">2.94</td><td align="center" rowspan="1" colspan="1">7.76E-06</td></tr></tbody></table><table-wrap-foot><fn id="TFN11"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Gene Expression and Pathway Analysis in Patients with POAF+NCD vs.
POAF+NORM.</title><p>
<xref ref-type="fig" rid="f2">Figure 2</xref> shows the distribution of
regulated genes by fold-change for each time point. Pre-CPB 42 genes were
significantly regulated in the POAF+NCD group compared to POAF+NORM, of which 29
were named. Of these, 18 were up-regulated, while 11 were down-regulated. These
genes were associated with cardiovascular disease, nervous system function, and
inflammation. Post-CPB, the number of regulated genes was 39, of which 37 were
named. Sixteen of these 37 were up-regulated, while 21 were down-regulated.
Pathway analysis demonstrated that these genes serve roles in cardiovascular
disease and inflammation. At 4D, the number of regulated genes increased to 72,
of which 54 were named. Twenty-seven of these were up-regulated, while 27 were
down-regulated. IPA analysis again revealed that several genes affect
cardiovascular disease, inflammation, and cell death. Selected genes grouped by
pathophysiologic function for the POAF+NCD vs. POAF+NORM comparisons are found
in <xref ref-type="table" rid="t11">Tables 11</xref>-<xref ref-type="table" rid="t13">13</xref>. While the majority of the genes identified for these
comparisons were distinct from that of POAF+NCD vs. SR+NORM across all time
points, multiple genes overlap and are listed in <xref ref-type="table" rid="t14">Table 14</xref>.</p><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Distribution of genes regulated for POAF+NCD <italic>vs.</italic>
POAF+NORM.</p></caption><graphic xlink:href="rbccv-30-05-0520-g02"/></fig><table-wrap id="t11" orientation="portrait" position="float"><label>Table 11</label><caption><p>Pre-CPB gene expression in patients with POAF+NCD compared with POAF+NORM
- selected genes grouped by potential pathophysiologic function.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cardiovascular
disease/function</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">NFATC1</td><td rowspan="1" colspan="1">nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 1</td><td align="center" rowspan="1" colspan="1">1.61</td><td align="center" rowspan="1" colspan="1">6.46E-05</td></tr><tr><td rowspan="1" colspan="1">TUBG1</td><td rowspan="1" colspan="1">tubulin, gamma 1</td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">8.71E-05</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">MCF2L</td><td rowspan="1" colspan="1">MCF.2 cell line derived transforming sequence-like</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">4.17E-05</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Nervous system function</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">FKRP</td><td rowspan="1" colspan="1">fukutin related protein</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">4.17E-05</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">KCNIP3</td><td rowspan="1" colspan="1">Kv channel interacting protein 3, calsenilin</td><td align="center" rowspan="1" colspan="1">1.58</td><td align="center" rowspan="1" colspan="1">6.31E-19</td></tr></tbody></table><table-wrap-foot><fn id="TFN12"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t12" orientation="portrait" position="float"><label>Table 12</label><caption><p>Post-CPB gene expression in patients with POAF+NCD compared with
POAF+NORM &#x02013; selected genes grouped by potential pathophysiologic
function.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">Accession ID </th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cardiovascular
disease/function</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">MAPK14</td><td rowspan="1" colspan="1">mitogen-activated protein kinase 14</td><td align="center" rowspan="1" colspan="1">1.98</td><td align="center" rowspan="1" colspan="1">6.31E-24</td></tr><tr><td rowspan="1" colspan="1">SYNE1</td><td rowspan="1" colspan="1">spectrin repeat containing, nuclear envelope 1</td><td align="center" rowspan="1" colspan="1">2.74</td><td align="center" rowspan="1" colspan="1">1.26E-04</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">CDS2</td><td rowspan="1" colspan="1">CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase)
2</td><td align="center" rowspan="1" colspan="1">2.03</td><td align="center" rowspan="1" colspan="1">3.09E-09</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Inflammation</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">HIVEP2</td><td rowspan="1" colspan="1">human immunodeficiency virus type I enhancer binding protein
2</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">6.03E-05</td></tr></tbody></table><table-wrap-foot><fn id="TFN13"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t13" orientation="portrait" position="float"><label>Table 13</label><caption><p>4D Gene expression in patients with POAF+NCD compared with POAF+NORM -
selected genes grouped by potential patho-physiologic function.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cardiovascular disease</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">CBL</td><td rowspan="1" colspan="1">Cbl proto-oncogene, E3 ubiquitin protein ligase</td><td align="center" rowspan="1" colspan="1">0.64</td><td align="center" rowspan="1" colspan="1">2.24E-10</td></tr><tr><td rowspan="1" colspan="1">SERPINE1</td><td rowspan="1" colspan="1">serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">2.69E-06</td></tr><tr><td rowspan="1" colspan="1">BCL2L1</td><td rowspan="1" colspan="1">BCL2-like 1</td><td align="center" rowspan="1" colspan="1">2.75</td><td align="center" rowspan="1" colspan="1">3.09E-06</td></tr><tr><td rowspan="1" colspan="1">MED1</td><td rowspan="1" colspan="1">mediator complex subunit 1</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">3.09E-09</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">RASSF1</td><td rowspan="1" colspan="1">Ras association (RalGDS/AF-6) domain family member 1</td><td align="center" rowspan="1" colspan="1">0.46</td><td align="center" rowspan="1" colspan="1">3.98E-11</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Cell death/survival</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">IDE</td><td rowspan="1" colspan="1">insulin-degrading enzyme</td><td align="center" rowspan="1" colspan="1">1.56</td><td align="center" rowspan="1" colspan="1">1.05E-05</td></tr><tr><td rowspan="1" colspan="1">RAB32</td><td rowspan="1" colspan="1">RAB32, member RAS oncogene family</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">3.24E-06</td></tr><tr><td rowspan="1" colspan="1">CDC42BPA</td><td rowspan="1" colspan="1">CDC42 binding protein kinase alpha (DMPK-like)</td><td align="center" rowspan="1" colspan="1">2.24</td><td align="center" rowspan="1" colspan="1">1.70E-09</td></tr><tr><td rowspan="1" colspan="1">DOCK1</td><td rowspan="1" colspan="1">dedicator of cytokinesis 1</td><td align="center" rowspan="1" colspan="1">2.10</td><td align="center" rowspan="1" colspan="1">7.94E-49</td></tr><tr><td rowspan="1" colspan="1">L1CAM</td><td rowspan="1" colspan="1">L1 cell adhesion molecule</td><td align="center" rowspan="1" colspan="1">1.60</td><td align="center" rowspan="1" colspan="1">5.01E-11</td></tr><tr><td rowspan="1" colspan="1">PTPN9</td><td rowspan="1" colspan="1">protein tyrosine phosphatase, non-receptor type 9</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">1.15E-04</td></tr><tr><td rowspan="1" colspan="1">SMC3</td><td rowspan="1" colspan="1">structural maintenance of chromosomes 3</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">1.38E-07</td></tr><tr><td rowspan="1" colspan="1">DDX17</td><td rowspan="1" colspan="1">DEAD (Asp-Glu-Ala-Asp) box helicase 17</td><td align="center" rowspan="1" colspan="1">6.55</td><td align="center" rowspan="1" colspan="1">2.51E-25</td></tr><tr><td rowspan="1" colspan="1">GRB10</td><td rowspan="1" colspan="1">growth factor receptor-bound protein 10</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">1.45E-09</td></tr><tr><td rowspan="1" colspan="1">PRDM2</td><td rowspan="1" colspan="1">PR domain containing 2, with ZNF domain</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">8.13E-06</td></tr><tr><td rowspan="1" colspan="1">TCF4</td><td rowspan="1" colspan="1">transcription factor 4</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">1.58E-06</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">ZEB1</td><td rowspan="1" colspan="1">zinc finger E-box binding homeobox 1</td><td align="center" rowspan="1" colspan="1">0.56</td><td align="center" rowspan="1" colspan="1">1.10E-06</td></tr><tr><td style="border-right-style:hidden" rowspan="1" colspan="1">Inflammation</td><td colspan="3" rowspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">ADRBK2</td><td rowspan="1" colspan="1">adrenergic, beta, receptor kinase 2</td><td align="center" rowspan="1" colspan="1">0.22</td><td align="center" rowspan="1" colspan="1">1.29E-09</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">NCR1</td><td rowspan="1" colspan="1">natural cytotoxicity triggering receptor 1</td><td align="center" rowspan="1" colspan="1">2.45</td><td align="center" rowspan="1" colspan="1">2.04E-07</td></tr></tbody></table><table-wrap-foot><fn id="TFN14"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t14" orientation="portrait" position="float"><label>Table 14</label><caption><p>Significantly regulated genes overlapping across multiple
comparisons.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">Comparisons</th><th align="left" rowspan="1" colspan="1">Overlapping Regulated Genes</th></tr></thead><tbody><tr><td style="border-bottom-style:hidden" rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic>
SR+NORM (Pre-CPB) </td><td rowspan="2" colspan="1">ca11, kcnip3, mcf2l, mmp11, nutm2f/nutm2g, pycr1,
vgll1, wiz</td></tr><tr><td rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic> AF+NORM (Pre-CPB)</td></tr><tr><td style="border-bottom-style:hidden" rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic>
SR+NORM (Post-CPB) </td><td rowspan="2" colspan="1">cds2, clec2b, dach1, fkbp9, gtf2h2, hist2h2be,
mapk14, slc39a8, sult1b1, syne1, timm23, tor1aip2, yipf4,
znf350</td></tr><tr><td rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic> AF+NORM (Post-CPB)</td></tr><tr><td style="border-bottom-style:hidden" rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic>
SR+NORM (4D) </td><td rowspan="2" colspan="1">agpat6, bcl2l1, c20orf203, casc7, cdc42bpa, cdca7,
ddx17, dld, dock1, frmd8, glcci1, grb10, ide, mmd, ncr1, nedd4l,
reep1, rpl10, smc3, ube2h</td></tr><tr><td rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic> AF+NORM (4D)</td></tr><tr><td style="border-bottom-style:hidden" rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic>
SR+NORM (Post-CPB) </td><td rowspan="3" colspan="1">UBE2H</td></tr><tr><td style="border-bottom-style:hidden" rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic>
SR+NORM (4D) </td></tr><tr><td rowspan="1" colspan="1">POAF+NCD <italic>vs.</italic> AF+NORM (4D)</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>AF and NCD after cardiac surgery have each been extensively studied. Much of the
literature for POAF has pointed to inflammation and oxidative stress as promoting
factors. Indeed, prior work from our group demonstrated significantly elevated
genomic markers of oxidative stress in the blood of patients who develop POAF after
CPB<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. We
similarly used microarray to study NCD patients and found increased expression of
blood inflammatory mediators from those undergoing CPB<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Given that the genomic
regulation of systemic cytotoxic insults such as oxidation and inflammation appear
to promote POAF and NCD when studied individually, we sought to determine if genomic
responses differ in patients who develop both complications.</p><p>Our current microarray study shows that the expression profiles of patients who
develop both POAF and NCD after CPB differ from those who develop neither
complication nor POAF alone. The greatest amount of gene regulation occurred
postoperatively, suggesting that CPB may induce a differential genomic response in
susceptible patients. Furthermore, POAF+NCD vs. POAF+NORM had the most gene
regulation at 4D, while POAF+NCD vs. SR+NORM had the most gene regulation post-CPB
with a largely different set of genes identified. This suggests that POAF and NCD
after CPB may be linked pathophysiologically through mechanisms distinct from those
inducing POAF alone, with more genomic changes occurring at an earlier stage.</p><p>Many genes regulated post-CPB in POAF+NCD vs. SR+NORM are associated with pathologic
cardiac remodeling. One such gene includes BMX, a non-receptor tyrosine kinase.
Mitchell-Jordan et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> demonstrated that BMX-knockout mice were resistant to
massive cardiac hypertrophy following transverse aortic constriction relative to
wild type, indicating a significant role for BMX in cardiac remodeling. If the
impressive 7.32-fold up-regulation of BMX in the blood of our POAF+NCD patients also
reflects their myocardial expression, excess cardiac remodeling after CPB may be a
predisposing factor for POAF and NCD. Additional up-regulated genes identified in
this group with reported roles in cardiac remodeling include EPAS1, HGF, and
MAPK14<sup>[<xref rid="r22" ref-type="bibr">22</xref>-<xref rid="r24" ref-type="bibr">24</xref>]</sup>. While there is much evidence for oxidative stress in
cardiac remodeling and AF<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>, our study found genes implicated in remodeling but not
oxidative stress, perhaps due to our limited sample size. However, while Ramlawi et
al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>
demonstrated genomic regulation of oxidative stress in POAF patients, they did not
report genes directly related to cardiac remodeling. This difference may lie in the
fact that our patients developed NCD in addition to POAF, introducing a potential
association of cardiac remodeling with secondary neurologic effects.</p><p>Several genes identified in the POAF+NCD vs. SR+NORM comparison are also directly
implicated in neurologic dysfunction. KIDINS220 was up-regulated post-CPB and has
been shown to accumulate with tau protein in the brains of Alzheimer Disease
patients<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. At 4D, there was also increased expression of PLXNB1,
which controls the behavior of microtubule tips and dendrite
morphology<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. Given its critical role in regulating the cytoskeleton
and dendrite growth, it is postulated to be involved in the pathogenesis of several
neurological disorders.</p><p>Genes related to inflammation and cell death were also identified in POAF+NCD vs.
SR+NORM. KIDINS200, discussed above, has a known role in T-cell receptor-mediated
T-cell activation in addition to its neurologic functions<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. At 4D, up-regulated
pro-inflammatory genes include NCR1 and DOCK. NCR1 encodes a natural killer cell
receptor that triggers cytotoxicity, while DOCK1 is involved in cytoskeletal
rearrangements required for phagocytosis<sup>[<xref rid="r29" ref-type="bibr">29</xref>,<xref rid="r30" ref-type="bibr">30</xref>]</sup> Genes involved with protein degradation were also
identified at 4D, including NEDD4L and UBE2H. NEDD4L encodes an E3 ubiquitin ligase
and UBEH2 encodes ubiquitin-conjugating enzyme E2H, both of which target proteins
for lysosomal degradation<sup>[<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r32" ref-type="bibr">32</xref>]</sup>. These genes have no established relationship to either
POAF or NCD after CPB, but given that systemic inflammatory and catabolic processes
are known contributors to both complications, the regulation of these proteins at
the genomic level may be relevant<sup>[<xref rid="r33" ref-type="bibr">33</xref>-<xref rid="r36" ref-type="bibr">36</xref>]</sup>.</p><p>Our study has limitations, the most significant of which is the size of our patient
population. A larger study may allow for the identification of more genes that may
characterize complete pathways, such as the oxidative stress response, as opposed to
our identification of several isolated genes related to various pathways. While our
patients were well matched, our sample size also precludes us from respecting
Hardy-Weinberg Equilibrium. However, we hope that our findings stimulate interest in
larger studies of this nature.</p><p>Another limitation is our profiling gene expression in blood rather than heart or
brain tissues, both of which were not feasible in this study and would not be a
practical option for future patient management strategies. It is unknown if the
genes involved with cardiovascular and neurologic function identified in blood
reflect pathways in the heart and brain. However, several genes we identified may
have systemic effects through inflammation and cell death that may secondarily
damage both heart and brain tissue and predispose these individuals to POAF and
NCD.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Our findings may expand what is known about the pathophysiology underlying POAF and
NCD. While we cannot assert a true genetic association between POAF and NCD given
our limited sample size, our results suggest that differential genomic responses
existed in our study sample of patients who developed both complications after
cardiac surgery. There may have been an influence of pathologic cardiac remodeling
and involvement of genes with known roles in inflammation, cell death, and nervous
system function that may have promoted POAF and NCD in our patient population. We
hope that the database of regulated genes provided by this work sparks further study
of differentially expressed pathways that may deepen our understanding of these
important and costly complications and potentially offer means of risk
stratification and improved patient management.</p><table-wrap id="t16" orientation="portrait" position="float"><table frame="hsides" rules="groups"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th colspan="2" align="left" rowspan="1">
<bold>Authors' roles &#x00026; responsibilities</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">RSD</td><td rowspan="1" colspan="1">Analysis or interpretation of data; statistical analysis; final
approval of the manuscript; study design</td></tr><tr><td rowspan="1" colspan="1">AAS</td><td rowspan="1" colspan="1">Study design; final approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">NYE</td><td rowspan="1" colspan="1">Study design; final approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">BR</td><td rowspan="1" colspan="1">Study design; final approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">FWS</td><td rowspan="1" colspan="1">Final approval of the manuscript; study design; implementation of
projects/experiments</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out in the Division of Cardiothoracic Surgery,
Cardiovascular Research Center, Warren Alpert Medical School of Brown
University, Providence, RI.</p></fn><fn fn-type="financial-disclosure"><p>Financial Support: Funding for this research was provided by the National Heart,
Lung, and Blood Institute (R01HL46716, Dr. Sellke; T35HL094308, Dr. Dalal) and
NIH Training grant 5T32-HL094300-03 (Drs. Sabe and Elmadhun).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Taha</surname><given-names>R</given-names></name><name><surname>Gauvin</surname><given-names>D</given-names></name><name><surname>Othmen</surname><given-names>LB</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Blaise</surname><given-names>G</given-names></name></person-group><article-title>Postoperative cognitive dysfunction after cardiac
surgery</article-title><source>Chest</source><year>2005</year><volume>128</volume><issue>5</issue><fpage>3664</fpage><lpage>3670</lpage><pub-id pub-id-type="pmid">16304328</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auer</surname><given-names>J</given-names></name><name><surname>Weber</surname><given-names>T</given-names></name><name><surname>Berent</surname><given-names>R</given-names></name><name><surname>Ng</surname><given-names>CK</given-names></name><name><surname>Lamm</surname><given-names>G</given-names></name><name><surname>Eber</surname><given-names>B</given-names></name></person-group><article-title>Risk factors of postoperative atrial fibrillation after cardiac
surgery</article-title><source>J Card Surg</source><year>2005</year><volume>20</volume><issue>5</issue><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">16153272</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eagle</surname><given-names>KA</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><name><surname>Davidoff</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>FH</given-names></name><name><surname>Ewy</surname><given-names>GA</given-names></name><name><surname>Gardner</surname><given-names>TJ</given-names></name><etal/><collab>American College of Cardiology</collab><collab>American Heart Association</collab></person-group><article-title>ACC/AHA 2004 guideline update for coronary artery bypass graft
surgery: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee to Update the 1999
Guidelines for Coronary Artery Bypass Graft Surgery)</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>14</issue><fpage>e340</fpage><lpage>e437</lpage><pub-id pub-id-type="pmid">15466654</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murkin</surname><given-names>JM</given-names></name></person-group><article-title>Etiology and incidence of brain dysfunction after cardiac
surgery</article-title><source>J Cardiothorac Vasc Anesth</source><year>1999</year><volume>13</volume><issue>suppl 1</issue><fpage>12</fpage><lpage>17</lpage><comment>discussion 36-7</comment><pub-id pub-id-type="pmid">10468244</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>MF</given-names></name><name><surname>Kirchner</surname><given-names>JL</given-names></name><name><surname>Phillips-Bute</surname><given-names>B</given-names></name><name><surname>Gaver</surname><given-names>B</given-names></name><name><surname>Grocott</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>RH</given-names></name><etal/><collab>Neurological Outcome Research Group</collab><collab>Cardiothoracic Anesthesiology Research Endeavors
Investigators</collab></person-group><article-title>Longitudinal assessment of neurocognitive function after
coronary-artery bypass surgery</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><issue>6</issue><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">11172175</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creswell</surname><given-names>LL</given-names></name><name><surname>Schuessler</surname><given-names>RB</given-names></name><name><surname>Rosenbloom</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>JL</given-names></name></person-group><article-title>Hazards of postoperative atrial arrhythmias</article-title><source>Ann Thorac Surg</source><year>1993</year><volume>56</volume><issue>3</issue><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">8379728</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aranki</surname><given-names>SF</given-names></name><name><surname>Shaw</surname><given-names>DP</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Rizzo</surname><given-names>RJ</given-names></name><name><surname>Couper</surname><given-names>GS</given-names></name><name><surname>VanderVliet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictors of atrial fibrillation after coronary artery surgery.
Current trends and impact on hospital resources</article-title><source>Circulation</source><year>1996</year><volume>94</volume><issue>3</issue><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">8759081</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ommen</surname><given-names>SR</given-names></name><name><surname>Odell</surname><given-names>JA</given-names></name><name><surname>Stanton</surname><given-names>MS</given-names></name></person-group><article-title>Atrial arrhythmias after cardiothoracic surgery</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><issue>20</issue><fpage>1429</fpage><lpage>1434</lpage><pub-id pub-id-type="pmid">9145681</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontes</surname><given-names>ML</given-names></name><name><surname>Mathew</surname><given-names>JP</given-names></name><name><surname>Rinder</surname><given-names>HM</given-names></name><name><surname>Zelterman</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>BR</given-names></name><name><surname>Rinder</surname><given-names>CS</given-names></name><collab>Multicenter Study of Perioperative Ischemia (McSPI) Research
Group</collab></person-group><article-title>Atrial fibrillation after cardiac surgery/cardiopulmonary bypass
is associated with monocyte activation</article-title><source>Anesth Analg</source><year>2005</year><volume>101</volume><issue>1</issue><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15976199</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiroshita-Takeshita</surname><given-names>A</given-names></name><name><surname>Schram</surname><given-names>G</given-names></name><name><surname>Lavoie</surname><given-names>J</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Effect of simvastatin and antioxidant vitamins on atrial
fibrillation promotion by atrial-tachycardia remodeling in
dogs</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>16</issue><fpage>2313</fpage><lpage>2319</lpage><pub-id pub-id-type="pmid">15477401</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramlawi</surname><given-names>B</given-names></name><name><surname>Out</surname><given-names>H</given-names></name><name><surname>Mieno</surname><given-names>S</given-names></name><name><surname>Boodhwani</surname><given-names>M</given-names></name><name><surname>Sodha</surname><given-names>NR</given-names></name><name><surname>Clements</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Oxidative stress and atrial fibrillation after cardiac surgery: a
case-control study</article-title><source>Ann Thorac Surg</source><year>2007</year><volume>84</volume><issue>4</issue><fpage>1166</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">17888965</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>JP</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Savino</surname><given-names>JS</given-names></name><name><surname>Friedman</surname><given-names>AS</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Mangano</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Atrial fibrillation following coronary artery bypass graft
surgery: predictors, outcomes, and resource utilization. MultiCenter Study
of Perioperative Ischemia Research Group</article-title><source>JAMA</source><year>1996</year><volume>276</volume><issue>4</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">8656542</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>TO</given-names></name><name><surname>Mackensen</surname><given-names>GB</given-names></name><name><surname>Grocott</surname><given-names>HP</given-names></name><name><surname>White</surname><given-names>WD</given-names></name><name><surname>Blumenthal</surname><given-names>JA</given-names></name><name><surname>Laskowitz</surname><given-names>DT</given-names></name><etal/><collab>Neurological Outcome Research Group</collab><collab>CARE Investigators of the Duke Heart Center</collab></person-group><article-title>The impact of postoperative atrial fibrillation on neurocognitive
outcome after coronary artery bypass graft surgery</article-title><source>Anesth Analg</source><year>2002</year><volume>94</volume><issue>2</issue><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">11812686</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabe</surname><given-names>AA</given-names></name><name><surname>Dalal</surname><given-names>RS</given-names></name><name><surname>Chu</surname><given-names>LM</given-names></name><name><surname>Elmadhun</surname><given-names>NY</given-names></name><name><surname>Ramlawi</surname><given-names>B</given-names></name><name><surname>Bianchi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preoperative gene expression may be associated with
neurocognitive decline after cardiopulmonary bypass</article-title><source>J Thorac Cardiovasc Surg</source><year>2015</year><volume>149</volume><issue>2</issue><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">25483902</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murkin</surname><given-names>JM</given-names></name><name><surname>Newman</surname><given-names>SP</given-names></name><name><surname>Stump</surname><given-names>DA</given-names></name><name><surname>Blumenthal</surname><given-names>JA</given-names></name></person-group><article-title>Statement of consensus on assessment of neurobehavioral outcomes
after cardiac surgery</article-title><source>Ann Thorac Surg</source><year>1995</year><volume>59</volume><issue>5</issue><fpage>1289</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">7733754</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Otu</surname><given-names>H</given-names></name><name><surname>Spentzos</surname><given-names>D</given-names></name><name><surname>Kolia</surname><given-names>S</given-names></name><name><surname>Inan</surname><given-names>M</given-names></name><name><surname>Beecken</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Gene signatures of progression and metastasis in renal cell
cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>16</issue><fpage>5730</fpage><lpage>5739</lpage><pub-id pub-id-type="pmid">16115910</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruel</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>C</given-names></name><name><surname>Khan</surname><given-names>TA</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Liddicoat</surname><given-names>JR</given-names></name><name><surname>Voisine</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gene expression profile after cardiopulmonary bypass and
cardioplegic arrest</article-title><source>J Thorac Cardiovasc Surg</source><year>2003</year><volume>126</volume><issue>5</issue><fpage>1521</fpage><lpage>1530</lpage><pub-id pub-id-type="pmid">14666028</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name></person-group><article-title>Model-based analysis of oligonucleotide arrays: expression index
computation and outlier detection</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">11134512</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalman</surname><given-names>MR</given-names></name><name><surname>Deeter</surname><given-names>A</given-names></name><name><surname>Nimishakavi</surname><given-names>G</given-names></name><name><surname>Duan</surname><given-names>ZH</given-names></name></person-group><article-title>Fold change and p-value cutoffs significantly alter microarray
interpretations</article-title><source>BMC Bioinformatics</source><year>2012</year><volume>13</volume><issue>Suppl 2</issue><fpage>S11</fpage><lpage>S11</lpage></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramlawi</surname><given-names>B</given-names></name><name><surname>Otu</surname><given-names>H</given-names></name><name><surname>Rudolph</surname><given-names>JL</given-names></name><name><surname>Mieno</surname><given-names>S</given-names></name><name><surname>Kohane</surname><given-names>IS</given-names></name><name><surname>Can</surname><given-names>H</given-names></name><etal/></person-group><article-title>Genomic expression pathways associated with brain injury after
cardiopulmonary bypass</article-title><source>J Thorac Cardiovasc Surg</source><year>2007</year><volume>134</volume><issue>4</issue><fpage>996</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">17903520</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell-Jordan</surname><given-names>SA</given-names></name><name><surname>Holopainen</surname><given-names>T</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Warburton</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Loss of Bmx nonreceptor tyrosine kinase prevents pressure
overload-induced cardiac hypertrophy</article-title><source>Circ Res</source><year>2008</year><volume>103</volume><issue>12</issue><fpage>1359</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">18988895</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scortegagna</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><name><surname>Oktay</surname><given-names>Y</given-names></name><name><surname>Gaur</surname><given-names>A</given-names></name><name><surname>Thurmond</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Multiple organ pathology, metabolic abnormalities and impaired
homeostasis of reactive oxygen species in Epas1-/- mice</article-title><source>Nat Genet</source><year>2003</year><volume>35</volume><issue>4</issue><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">14608355</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>AL</given-names></name><name><surname>Ou</surname><given-names>CW</given-names></name><name><surname>He</surname><given-names>ZC</given-names></name><name><surname>Liu</surname><given-names>QC</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>MS</given-names></name></person-group><article-title>Effect of hepatocyte growth factor and angiotensin II on rat
cardiomyocyte hypertrophy</article-title><source>Braz J Med Biol Res</source><year>2012</year><volume>45</volume><issue>12</issue><fpage>1150</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">23044624</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Kovacs</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Muslin</surname><given-names>AJ</given-names></name></person-group><article-title>Role of p38alpha MAPK in cardiac apoptosis and remodeling after
myocardial infarction</article-title><source>J Mol Cell Cardiol</source><year>2005</year><volume>38</volume><issue>4</issue><fpage>617</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">15808838</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korantzopoulos</surname><given-names>P</given-names></name><name><surname>Kolettis</surname><given-names>T</given-names></name><name><surname>Siogas</surname><given-names>K</given-names></name><name><surname>Goudevenos</surname><given-names>J</given-names></name></person-group><article-title>Atrial fibrillation and electrical remodeling: the potential role
of inflammation and oxidative stress</article-title><source>Med Sci Monit</source><year>2003</year><volume>9</volume><issue>9</issue><fpage>RA225</fpage><lpage>RA229</lpage><pub-id pub-id-type="pmid">12960937</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Men&#x000e9;ndez</surname><given-names>C</given-names></name><name><surname>Gamir-Morralla</surname><given-names>A</given-names></name><name><surname>Jurado-Arjona</surname><given-names>J</given-names></name><name><surname>Higuero</surname><given-names>AM</given-names></name><name><surname>Campanero</surname><given-names>MR</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><etal/></person-group><article-title>Kidins220 accumulates with tau in human Alzheimer's disease and
related models: modulation of its calpain-processing by GSK3&#x000df;/PP1
imbalance</article-title><source>Hum Mol Genet</source><year>2013</year><volume>22</volume><issue>3</issue><fpage>466</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">23118350</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laht</surname><given-names>P</given-names></name><name><surname>Otsus</surname><given-names>M</given-names></name><name><surname>Remm</surname><given-names>J</given-names></name><name><surname>Veske</surname><given-names>A</given-names></name></person-group><article-title>B-plexins control microtubule dynamics and dendrite morphology of
hippocampal neurons</article-title><source>Exp Cell Res</source><year>2014</year><volume>326</volume><issue>1</issue><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">24954409</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deswal</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>A</given-names></name><name><surname>Fiala</surname><given-names>GJ</given-names></name><name><surname>Eisenhardt</surname><given-names>AE</given-names></name><name><surname>Schmitt</surname><given-names>LC</given-names></name><name><surname>Salek</surname><given-names>M</given-names></name><etal/></person-group><article-title>Kidins220/ARMS associates with B-Raf and the TCR, promoting
sustained Erk signaling in T cells</article-title><source>J Immunol</source><year>2013</year><volume>190</volume><issue>5</issue><fpage>1927</fpage><lpage>1935</lpage><pub-id pub-id-type="pmid">23359496</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pessino</surname><given-names>A</given-names></name><name><surname>Sivori</surname><given-names>S</given-names></name><name><surname>Bottino</surname><given-names>C</given-names></name><name><surname>Malaspina</surname><given-names>A</given-names></name><name><surname>Morelli</surname><given-names>L</given-names></name><name><surname>Moretta</surname><given-names>L</given-names></name><etal/></person-group><article-title>Molecular cloning of NKp46: a novel member of the immunoglobulin
superfamily involved in triggering of natural cytotoxicity</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><issue>5</issue><fpage>953</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">9730896</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YC</given-names></name><name><surname>Horvitz</surname><given-names>HR</given-names></name></person-group><article-title>C. elegans phagocytosis and cell-migration protein CED-5 is
similar to human DOCK180</article-title><source>Nature</source><year>1998</year><volume>392</volume><issue>6675</issue><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">9548255</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Snyder</surname><given-names>PM</given-names></name></person-group><article-title>Nedd4-2 phosphorylation induces serum and
glucocorticoid-regulated kinase (SGK) ubiquitination and
degradation</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>6</issue><fpage>4518</fpage><lpage>4523</lpage><pub-id pub-id-type="pmid">15576372</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>P</given-names></name><name><surname>Seufert</surname><given-names>W</given-names></name><name><surname>H&#x000f6;fferer</surname><given-names>L</given-names></name><name><surname>Kofler</surname><given-names>B</given-names></name><name><surname>Sachsenmaier</surname><given-names>C</given-names></name><name><surname>Herzog</surname><given-names>H</given-names></name><etal/></person-group><article-title>A human ubiquitin-conjugating enzyme homologous to yeast
UBC8</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><issue>12</issue><fpage>8797</fpage><lpage>8802</lpage><pub-id pub-id-type="pmid">8132613</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramlawi</surname><given-names>B</given-names></name><name><surname>Rudolph</surname><given-names>JL</given-names></name><name><surname>Mieno</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Boodwhani</surname><given-names>M</given-names></name><name><surname>Khabbaz</surname><given-names>K</given-names></name><etal/></person-group><article-title>C-Reactive protein and inflammatory response associated to
neurocognitive decline following cardiac surgery</article-title><source>Surgery</source><year>2006</year><volume>140</volume><issue>2</issue><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">16904973</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>AM</given-names></name><name><surname>Shipolini</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>MM</given-names></name><name><surname>Hurley</surname><given-names>R</given-names></name><name><surname>Cormack</surname><given-names>F</given-names></name></person-group><article-title>Fixing hearts and protecting minds: a review of the multiple,
interacting factors influencing cognitive function after coronary artery
bypass graft surgery</article-title><source>Circulation</source><year>2013</year><volume>128</volume><issue>2</issue><fpage>162</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">23836829</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontes</surname><given-names>ML</given-names></name><name><surname>Amar</surname><given-names>D</given-names></name><name><surname>Kulak</surname><given-names>A</given-names></name><name><surname>Koval</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group><article-title>Increased preoperative white blood cell count predicts
postoperative atrial fibrillation after coronary artery bypass
surgery</article-title><source>J Cardiothorac Vasc Anesth</source><year>2009</year><volume>23</volume><issue>4</issue><fpage>484</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">19362015</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canbaz</surname><given-names>S</given-names></name><name><surname>Erbas</surname><given-names>H</given-names></name><name><surname>Huseyin</surname><given-names>S</given-names></name><name><surname>Duran</surname><given-names>E</given-names></name></person-group><article-title>The role of inflammation in atrial fibrillation following open
heart surgery</article-title><source>J Int Med Res</source><year>2008</year><volume>36</volume><issue>5</issue><fpage>1070</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">18831903</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Post-CBP gene expression in patients with POAF+NCD compared with SR+NORM -
complete list.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ABHD13</td><td rowspan="1" colspan="1">abhydrolase domain containing 13</td><td align="center" rowspan="1" colspan="1">1.92</td><td align="center" rowspan="1" colspan="1">1.00E-05</td></tr><tr><td rowspan="1" colspan="1">ACOX1</td><td rowspan="1" colspan="1">acyl-CoA oxidase 1, palmitoyl</td><td align="center" rowspan="1" colspan="1">2.75</td><td align="center" rowspan="1" colspan="1">1.23E-04</td></tr><tr><td rowspan="1" colspan="1">ARPC1A</td><td rowspan="1" colspan="1">actin related protein 2/3 complex, subunit 1A, 41kDa</td><td align="center" rowspan="1" colspan="1">2.23</td><td align="center" rowspan="1" colspan="1">7.41E-05</td></tr><tr><td style="border-left-style:hidden" rowspan="1" colspan="1">BMX</td><td rowspan="1" colspan="1">BMX non-receptor tyrosine kinase</td><td align="center" rowspan="1" colspan="1">7.32</td><td align="center" rowspan="1" colspan="1">1.00E-14</td></tr><tr><td rowspan="1" colspan="1">C1GALT1C1</td><td rowspan="1" colspan="1">C1GALT1-specific chaperone 1</td><td align="center" rowspan="1" colspan="1">1.63</td><td align="center" rowspan="1" colspan="1">1.82E-08</td></tr><tr><td rowspan="1" colspan="1">C2orf76</td><td rowspan="1" colspan="1">chromosome 2 open reading frame 76</td><td align="center" rowspan="1" colspan="1">2.38</td><td align="center" rowspan="1" colspan="1">5.25E-08</td></tr><tr><td rowspan="1" colspan="1">C5orf30</td><td rowspan="1" colspan="1">chromosome 5 open reading frame 30</td><td align="center" rowspan="1" colspan="1">2.56</td><td align="center" rowspan="1" colspan="1">6.17E-06</td></tr><tr><td rowspan="1" colspan="1">CDS2</td><td rowspan="1" colspan="1">CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">4.07E-10</td></tr><tr><td rowspan="1" colspan="1">CEACAM21</td><td rowspan="1" colspan="1">carcinoembryonic antigen-related cell adhesion molecule 21</td><td align="center" rowspan="1" colspan="1">3.02</td><td align="center" rowspan="1" colspan="1">8.71E-05</td></tr><tr><td rowspan="1" colspan="1">CLEC12A</td><td rowspan="1" colspan="1">C-type lectin domain family 12, member A</td><td align="center" rowspan="1" colspan="1">1.57</td><td align="center" rowspan="1" colspan="1">2.09E-05</td></tr><tr><td rowspan="1" colspan="1">CLEC2B</td><td rowspan="1" colspan="1">C-type lectin domain family 2, member B</td><td align="center" rowspan="1" colspan="1">1.62</td><td align="center" rowspan="1" colspan="1">1.95E-05</td></tr><tr><td rowspan="1" colspan="1">CREBBP</td><td rowspan="1" colspan="1">CREB binding protein</td><td align="center" rowspan="1" colspan="1">1.83</td><td align="center" rowspan="1" colspan="1">1.29E-06</td></tr><tr><td rowspan="1" colspan="1">DAB2</td><td rowspan="1" colspan="1">Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)</td><td align="center" rowspan="1" colspan="1">2.23</td><td align="center" rowspan="1" colspan="1">8.51E-05</td></tr><tr><td rowspan="1" colspan="1">DACH1</td><td rowspan="1" colspan="1">dachshund homolog 1 (Drosophila)</td><td align="center" rowspan="1" colspan="1">3.27</td><td align="center" rowspan="1" colspan="1">5.01E-11</td></tr><tr><td rowspan="1" colspan="1">DNAJC5</td><td rowspan="1" colspan="1">DnaJ (Hsp40) homolog, subfamily C, member 5</td><td align="center" rowspan="1" colspan="1">1.51</td><td align="center" rowspan="1" colspan="1">8.32E-07</td></tr><tr><td rowspan="1" colspan="1">EPAS1</td><td rowspan="1" colspan="1">endothelial PAS domain protein 1</td><td align="center" rowspan="1" colspan="1">2.43</td><td align="center" rowspan="1" colspan="1">6.17E-05</td></tr><tr><td rowspan="1" colspan="1">FAM114A2</td><td rowspan="1" colspan="1">family with sequence similarity 114, member A2</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">2.04E-06</td></tr><tr><td rowspan="1" colspan="1">FAM200B</td><td rowspan="1" colspan="1">family with sequence similarity 200, member B</td><td align="center" rowspan="1" colspan="1">2.12</td><td align="center" rowspan="1" colspan="1">1.86E-05</td></tr><tr><td rowspan="1" colspan="1">FBXO28</td><td rowspan="1" colspan="1">F-box protein 28</td><td align="center" rowspan="1" colspan="1">1.59</td><td align="center" rowspan="1" colspan="1">9.33E-05</td></tr><tr><td rowspan="1" colspan="1">FKBP9</td><td rowspan="1" colspan="1">FK506 binding protein 9, 63 kDa</td><td align="center" rowspan="1" colspan="1">5.72</td><td align="center" rowspan="1" colspan="1">1.58E-12</td></tr><tr><td rowspan="1" colspan="1">GNG2</td><td rowspan="1" colspan="1">guanine nucleotide binding protein (G protein), gamma 2</td><td align="center" rowspan="1" colspan="1">1.69</td><td align="center" rowspan="1" colspan="1">6.03E-05</td></tr><tr><td rowspan="1" colspan="1">GTF2H2</td><td rowspan="1" colspan="1">general transcription factor IIH, polypeptide 2, 44kDa</td><td align="center" rowspan="1" colspan="1">3.37</td><td align="center" rowspan="1" colspan="1">2.09E-10</td></tr><tr><td rowspan="1" colspan="1">HGF</td><td rowspan="1" colspan="1">hepatocyte growth factor (hepapoietin A; scatter factor)</td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">3.47E-05</td></tr><tr><td rowspan="1" colspan="1">HIST2H2BE (includes others)</td><td rowspan="1" colspan="1">histone cluster 2, H2be</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">5.01E-28</td></tr><tr><td rowspan="1" colspan="1">HOOK3</td><td rowspan="1" colspan="1">hook homolog 3 (Drosophila)</td><td align="center" rowspan="1" colspan="1">2.19</td><td align="center" rowspan="1" colspan="1">1.12E-04</td></tr><tr><td rowspan="1" colspan="1">KIDINS220</td><td rowspan="1" colspan="1">kinase D-interacting substrate, 220kDa</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">7.08E-06</td></tr><tr><td rowspan="1" colspan="1">KLHL7</td><td rowspan="1" colspan="1">kelch-like family member 7</td><td align="center" rowspan="1" colspan="1">1.63</td><td align="center" rowspan="1" colspan="1">1.17E-04</td></tr><tr><td rowspan="1" colspan="1">KPNA1</td><td rowspan="1" colspan="1">karyopherin alpha 1 (importin alpha 5)</td><td align="center" rowspan="1" colspan="1">2.45</td><td align="center" rowspan="1" colspan="1">1.78E-05</td></tr><tr><td rowspan="1" colspan="1">LEMD2</td><td rowspan="1" colspan="1">LEM domain containing 2</td><td align="center" rowspan="1" colspan="1">1.59</td><td align="center" rowspan="1" colspan="1">1.66E-05</td></tr><tr><td rowspan="1" colspan="1">LOC100506229</td><td rowspan="1" colspan="1">uncharacterized LOC100506229</td><td align="center" rowspan="1" colspan="1">2.15</td><td align="center" rowspan="1" colspan="1">3.09E-05</td></tr><tr><td rowspan="1" colspan="1">LOC100506328</td><td rowspan="1" colspan="1">uncharacterized LOC100506328</td><td align="center" rowspan="1" colspan="1">9.36</td><td align="center" rowspan="1" colspan="1">2.51E-11</td></tr><tr><td rowspan="1" colspan="1">LOC285835</td><td rowspan="1" colspan="1">uncharacterized LOC285835</td><td align="center" rowspan="1" colspan="1">1.51</td><td align="center" rowspan="1" colspan="1">6.31E-05</td></tr><tr><td rowspan="1" colspan="1">MAPK14</td><td rowspan="1" colspan="1">mitogen-activated protein kinase 14</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">2.51E-28</td></tr><tr><td rowspan="1" colspan="1">MARCH5</td><td rowspan="1" colspan="1">membrane-associated ring finger (C3HC4) 5</td><td align="center" rowspan="1" colspan="1">3.07</td><td align="center" rowspan="1" colspan="1">5.50E-06</td></tr><tr><td rowspan="1" colspan="1">MLLT4</td><td rowspan="1" colspan="1">myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog,
Drosophila); translocated to, 4</td><td align="center" rowspan="1" colspan="1">1.57</td><td align="center" rowspan="1" colspan="1">9.77E-05</td></tr><tr><td rowspan="1" colspan="1">MTIF3</td><td rowspan="1" colspan="1">mitochondrial translational initiation factor 3</td><td align="center" rowspan="1" colspan="1">2.60</td><td align="center" rowspan="1" colspan="1">4.07E-05</td></tr><tr><td rowspan="1" colspan="1">NKAP</td><td rowspan="1" colspan="1">NFKB activating protein</td><td align="center" rowspan="1" colspan="1">3.08</td><td align="center" rowspan="1" colspan="1">3.63E-05</td></tr><tr><td rowspan="1" colspan="1">OXSR1</td><td rowspan="1" colspan="1">oxidative stress responsive 1</td><td align="center" rowspan="1" colspan="1">2.84</td><td align="center" rowspan="1" colspan="1">1.62E-08</td></tr><tr><td rowspan="1" colspan="1">PDSS1</td><td rowspan="1" colspan="1">prenyl (decaprenyl) diphosphate synthase, subunit 1</td><td align="center" rowspan="1" colspan="1">3.08</td><td align="center" rowspan="1" colspan="1">1.45E-05</td></tr><tr><td rowspan="1" colspan="1">PFKFB2</td><td rowspan="1" colspan="1">6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2</td><td align="center" rowspan="1" colspan="1">3.60</td><td align="center" rowspan="1" colspan="1">2.51E-06</td></tr><tr><td rowspan="1" colspan="1">PRKAG1</td><td rowspan="1" colspan="1">protein kinase, AMP-activated, gamma 1 non-catalytic subunit</td><td align="center" rowspan="1" colspan="1">2.73</td><td align="center" rowspan="1" colspan="1">5.13E-05</td></tr><tr><td rowspan="1" colspan="1">RASGEF1A</td><td rowspan="1" colspan="1">RasGEF domain family, member 1A</td><td align="center" rowspan="1" colspan="1">4.12</td><td align="center" rowspan="1" colspan="1">1.78E-05</td></tr><tr><td rowspan="1" colspan="1">RILPL1</td><td rowspan="1" colspan="1">Rab interacting lysosomal protein-like 1</td><td align="center" rowspan="1" colspan="1">1.89</td><td align="center" rowspan="1" colspan="1">6.03E-06</td></tr><tr><td rowspan="1" colspan="1">SFXN1</td><td rowspan="1" colspan="1">sideroflexin 1</td><td align="center" rowspan="1" colspan="1">2.59</td><td align="center" rowspan="1" colspan="1">1.02E-04</td></tr><tr><td rowspan="1" colspan="1">SLC39A8</td><td rowspan="1" colspan="1">solute carrier family 39 (zinc transporter), member 8</td><td align="center" rowspan="1" colspan="1">1.73</td><td align="center" rowspan="1" colspan="1">3.98E-13</td></tr><tr><td rowspan="1" colspan="1">ST6GALNAC3</td><td rowspan="1" colspan="1">ST6
(alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalac-tosaminide
alpha-2,6-sialyltransferase 3</td><td align="center" rowspan="1" colspan="1">2.77</td><td align="center" rowspan="1" colspan="1">5.50E-06</td></tr><tr><td rowspan="1" colspan="1">STAG1</td><td rowspan="1" colspan="1">stromal antigen 1</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">2.00E-16</td></tr><tr><td rowspan="1" colspan="1">SULT1B1</td><td rowspan="1" colspan="1">sulfotransferase family, cytosolic, 1B, member 1</td><td align="center" rowspan="1" colspan="1">5.57</td><td align="center" rowspan="1" colspan="1">3.47E-10</td></tr><tr><td rowspan="1" colspan="1">SYNE1</td><td rowspan="1" colspan="1">spectrin repeat containing, nuclear envelope 1</td><td align="center" rowspan="1" colspan="1">3.11</td><td align="center" rowspan="1" colspan="1">3.09E-06</td></tr><tr><td rowspan="1" colspan="1">TANK</td><td rowspan="1" colspan="1">TRAF family member-associated NFKB activator</td><td align="center" rowspan="1" colspan="1">1.94</td><td align="center" rowspan="1" colspan="1">3.24E-05</td></tr><tr><td rowspan="1" colspan="1">TIMM23</td><td rowspan="1" colspan="1">translocase of inner mitochondrial membrane 23 homolog (yeast)</td><td align="center" rowspan="1" colspan="1">1.84</td><td align="center" rowspan="1" colspan="1">2.51E-16</td></tr><tr><td rowspan="1" colspan="1">TMLHE</td><td rowspan="1" colspan="1">trimethyllysine hydroxylase, epsilon</td><td align="center" rowspan="1" colspan="1">1.95</td><td align="center" rowspan="1" colspan="1">3.47E-05</td></tr><tr><td rowspan="1" colspan="1">TOR1AIP2</td><td rowspan="1" colspan="1">torsin A interacting protein 2</td><td align="center" rowspan="1" colspan="1">1.55</td><td align="center" rowspan="1" colspan="1">6.31E-25</td></tr><tr><td rowspan="1" colspan="1">TRPS1</td><td rowspan="1" colspan="1">trichorhinophalangeal syndrome I</td><td align="center" rowspan="1" colspan="1">2.09</td><td align="center" rowspan="1" colspan="1">7.08E-05</td></tr><tr><td rowspan="1" colspan="1">UBE2H</td><td rowspan="1" colspan="1">ubiquitin-conjugating enzyme E2H</td><td align="center" rowspan="1" colspan="1">3.47</td><td align="center" rowspan="1" colspan="1">2.19E-07</td></tr><tr><td rowspan="1" colspan="1">VAMP3</td><td rowspan="1" colspan="1">vesicle-associated membrane protein 3</td><td align="center" rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">8.51E-05</td></tr><tr><td rowspan="1" colspan="1">WDFY3</td><td rowspan="1" colspan="1">WD repeat and FYVE domain containing 3</td><td align="center" rowspan="1" colspan="1">2.69</td><td align="center" rowspan="1" colspan="1">1.02E-05</td></tr><tr><td rowspan="1" colspan="1">YIPF4</td><td rowspan="1" colspan="1">Yip1 domain family, member 4</td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">1.23E-06</td></tr><tr><td rowspan="1" colspan="1">YKT6</td><td rowspan="1" colspan="1">YKT6 v-SNARE homolog (S. cerevisiae)</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">3.39E-05</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">ZNF350</td><td rowspan="1" colspan="1">zinc finger protein 350</td><td align="center" rowspan="1" colspan="1">1.57</td><td align="center" rowspan="1" colspan="1">5.13E-05</td></tr></tbody></table><table-wrap-foot><fn id="TFN04"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>4D gene expression in patients with POAF+NCD compared with SR+NORM - complete
list.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AGPAT6</td><td rowspan="1" colspan="1">1-acylglycerol-3-phosphate O-acyltransferase 6</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">5.61E-04</td></tr><tr><td rowspan="1" colspan="1">ATP13A4</td><td rowspan="1" colspan="1">ATPase type 13A4</td><td align="center" rowspan="1" colspan="1">1.63</td><td align="center" rowspan="1" colspan="1">6.46E-06</td></tr><tr><td rowspan="1" colspan="1">BCL2L1</td><td rowspan="1" colspan="1">BCL2-like 1</td><td align="center" rowspan="1" colspan="1">3.17</td><td align="center" rowspan="1" colspan="1">1.58E-13</td></tr><tr><td rowspan="1" colspan="1">C20orf203</td><td rowspan="1" colspan="1">chromosome 20 open reading frame 203</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">4.37E-07</td></tr><tr><td rowspan="1" colspan="1">CASC7</td><td rowspan="1" colspan="1">cancer susceptibility candidate 7 (non-protein coding)</td><td align="center" rowspan="1" colspan="1">1.70</td><td align="center" rowspan="1" colspan="1">3.98E-11</td></tr><tr><td rowspan="1" colspan="1">CDC42BPA</td><td rowspan="1" colspan="1">CDC42 binding protein kinase alpha (DMPK-like)</td><td align="center" rowspan="1" colspan="1">1.94</td><td align="center" rowspan="1" colspan="1">1.86E-08</td></tr><tr><td rowspan="1" colspan="1">CDCA7</td><td rowspan="1" colspan="1">cell division cycle associated 7</td><td align="center" rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">5.75E-05</td></tr><tr><td rowspan="1" colspan="1">CTSO</td><td rowspan="1" colspan="1">cathepsin O</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">8.71E-05</td></tr><tr><td rowspan="1" colspan="1">DDX17</td><td rowspan="1" colspan="1">DEAD (Asp-Glu-Ala-Asp) box helicase 17</td><td align="center" rowspan="1" colspan="1">7.10</td><td align="center" rowspan="1" colspan="1">5.01E-27</td></tr><tr><td rowspan="1" colspan="1">DLD</td><td rowspan="1" colspan="1">dihydrolipoamide dehydrogenase</td><td align="center" rowspan="1" colspan="1">2.13</td><td align="center" rowspan="1" colspan="1">3.16E-14</td></tr><tr><td rowspan="1" colspan="1">DOCK1</td><td rowspan="1" colspan="1">dedicator of cytokinesis 1</td><td align="center" rowspan="1" colspan="1">2.09</td><td align="center" rowspan="1" colspan="1">6.31E-50</td></tr><tr><td rowspan="1" colspan="1">DSC2</td><td rowspan="1" colspan="1">desmocollin 2</td><td align="center" rowspan="1" colspan="1">2.01</td><td align="center" rowspan="1" colspan="1">4.07E-06</td></tr><tr><td rowspan="1" colspan="1">FRMD8</td><td rowspan="1" colspan="1">FERM domain containing 8</td><td align="center" rowspan="1" colspan="1">2.42</td><td align="center" rowspan="1" colspan="1">2.45E-06</td></tr><tr><td rowspan="1" colspan="1">GLCCI1</td><td rowspan="1" colspan="1">glucocorticoid induced transcript 1</td><td align="center" rowspan="1" colspan="1">2.61</td><td align="center" rowspan="1" colspan="1">3.16E-16</td></tr><tr><td rowspan="1" colspan="1">GRB10</td><td rowspan="1" colspan="1">growth factor receptor-bound protein 10</td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">3.16E-11</td></tr><tr><td rowspan="1" colspan="1">HNMT</td><td rowspan="1" colspan="1">histamine N-methyltransferase</td><td align="center" rowspan="1" colspan="1">1.65</td><td align="center" rowspan="1" colspan="1">1.05E-04</td></tr><tr><td rowspan="1" colspan="1">IDE</td><td rowspan="1" colspan="1">insulin-degrading enzyme</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">6.61E-06</td></tr><tr><td rowspan="1" colspan="1">LOC284080</td><td rowspan="1" colspan="1">uncharacterized LOC284080</td><td align="center" rowspan="1" colspan="1">1.51</td><td align="center" rowspan="1" colspan="1">8.13E-05</td></tr><tr><td rowspan="1" colspan="1">MMD</td><td rowspan="1" colspan="1">monocyte to macrophage differentiation-associated</td><td align="center" rowspan="1" colspan="1">1.57</td><td align="center" rowspan="1" colspan="1">2.00E-15</td></tr><tr><td rowspan="1" colspan="1">NCR1</td><td rowspan="1" colspan="1">natural cytotoxicity triggering receptor 1</td><td align="center" rowspan="1" colspan="1">1.90</td><td align="center" rowspan="1" colspan="1">2.57E-05</td></tr><tr><td rowspan="1" colspan="1">NEDD4L</td><td rowspan="1" colspan="1">neural precursor cell expressed, developmentally down-regulated 4-like,
E3 ubiquitin protein ligase</td><td align="center" rowspan="1" colspan="1">1.60</td><td align="center" rowspan="1" colspan="1">6.31E-11</td></tr><tr><td rowspan="1" colspan="1">PLXNB1</td><td rowspan="1" colspan="1">plexin B1</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">1.00E-15</td></tr><tr><td rowspan="1" colspan="1">PRKAA2</td><td rowspan="1" colspan="1">protein kinase, AMP-activated, alpha 2 catalytic subunit</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">5.37E-05</td></tr><tr><td rowspan="1" colspan="1">PRRT1</td><td rowspan="1" colspan="1">proline-rich transmembrane protein 1</td><td align="center" rowspan="1" colspan="1">1.98</td><td align="center" rowspan="1" colspan="1">3.98E-05</td></tr><tr><td rowspan="1" colspan="1">REEP1</td><td rowspan="1" colspan="1">receptor accessory protein 1</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">2.63E-07</td></tr><tr><td rowspan="1" colspan="1">RHCE/RHD</td><td rowspan="1" colspan="1">Rh blood group, D antigen</td><td align="center" rowspan="1" colspan="1">1.69</td><td align="center" rowspan="1" colspan="1">8.13E-05</td></tr><tr><td rowspan="1" colspan="1">RIOK3</td><td rowspan="1" colspan="1">RIO kinase 3</td><td align="center" rowspan="1" colspan="1">4.54</td><td align="center" rowspan="1" colspan="1">9.55E-05</td></tr><tr><td rowspan="1" colspan="1">RPL10</td><td rowspan="1" colspan="1">ribosomal protein L10</td><td align="center" rowspan="1" colspan="1">0.40</td><td align="center" rowspan="1" colspan="1">8.91E-05</td></tr><tr><td rowspan="1" colspan="1">RPL18</td><td rowspan="1" colspan="1">ribosomal protein L18</td><td align="center" rowspan="1" colspan="1">0.47</td><td align="center" rowspan="1" colspan="1">1.95E-05</td></tr><tr><td rowspan="1" colspan="1">SMC3</td><td rowspan="1" colspan="1">structural maintenance of chromosomes 3</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">4.47E-06</td></tr><tr><td rowspan="1" colspan="1">SRSF1</td><td rowspan="1" colspan="1">serine/arginine-rich splicing factor 1</td><td align="center" rowspan="1" colspan="1">2.04</td><td align="center" rowspan="1" colspan="1">4.37E-05</td></tr><tr><td rowspan="1" colspan="1">ST7</td><td rowspan="1" colspan="1">suppression of tumorigenicity 7</td><td align="center" rowspan="1" colspan="1">1.58</td><td align="center" rowspan="1" colspan="1">6.76E-05</td></tr><tr><td rowspan="1" colspan="1">TFAP2E</td><td rowspan="1" colspan="1">transcription factor AP-2 epsilon (activating enhancer binding protein 2
epsilon)</td><td align="center" rowspan="1" colspan="1">1.93</td><td align="center" rowspan="1" colspan="1">5.89E-06</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">UBE2H</td><td rowspan="1" colspan="1">ubiquitin-conjugating enzyme E2H</td><td align="center" rowspan="1" colspan="1">2.94</td><td align="center" rowspan="1" colspan="1">7.76E-06</td></tr></tbody></table><table-wrap-foot><fn id="TFN05"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Pre-CPB gene expression in patients with POAF+NCD compared with POAF+NORM -
complete list.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ACTR3BP5</td><td rowspan="1" colspan="1">ARP3 actin-related protein 3 homolog B (yeast) pseudogene 5</td><td align="center" rowspan="1" colspan="1">0.57</td><td align="center" rowspan="1" colspan="1">3.55E-09</td></tr><tr><td rowspan="1" colspan="1">AP5S1</td><td rowspan="1" colspan="1">adaptor-related protein complex 5, sigma 1 subunit</td><td align="center" rowspan="1" colspan="1">1.87</td><td align="center" rowspan="1" colspan="1">1.00E-04</td></tr><tr><td rowspan="1" colspan="1">C14orf166B</td><td rowspan="1" colspan="1">chromosome 14 open reading frame 166B</td><td align="center" rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">1.58E-12</td></tr><tr><td rowspan="1" colspan="1">CA11</td><td rowspan="1" colspan="1">carbonic anhydrase XI</td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">8.91E-06</td></tr><tr><td rowspan="1" colspan="1">CCDC36</td><td rowspan="1" colspan="1">coiled-coil domain containing 36</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">5.01E-21</td></tr><tr><td rowspan="1" colspan="1">CIZ1</td><td rowspan="1" colspan="1">CDKN1A interacting zinc finger protein 1</td><td align="center" rowspan="1" colspan="1">2.42</td><td align="center" rowspan="1" colspan="1">1.10E-04</td></tr><tr><td rowspan="1" colspan="1">FHAD1</td><td rowspan="1" colspan="1">forkhead-associated (FHA) phosphopeptide binding domain 1</td><td align="center" rowspan="1" colspan="1">1.51</td><td align="center" rowspan="1" colspan="1">6.31E-06</td></tr><tr><td rowspan="1" colspan="1">FKRP</td><td rowspan="1" colspan="1">fukutin related protein</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">4.17E-05</td></tr><tr><td rowspan="1" colspan="1">GTPBP3</td><td rowspan="1" colspan="1">GTP binding protein 3 (mitochondrial)</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">2.75E-05</td></tr><tr><td rowspan="1" colspan="1">KCNIP3</td><td rowspan="1" colspan="1">Kv channel interacting protein 3, calsenilin</td><td align="center" rowspan="1" colspan="1">1.58</td><td align="center" rowspan="1" colspan="1">6.31E-19</td></tr><tr><td rowspan="1" colspan="1">KHSRP</td><td rowspan="1" colspan="1">KH-type splicing regulatory protein</td><td align="center" rowspan="1" colspan="1">1.56</td><td align="center" rowspan="1" colspan="1">4.79E-10</td></tr><tr><td rowspan="1" colspan="1">LOC100507477</td><td rowspan="1" colspan="1">uncharacterized LOC100507477</td><td align="center" rowspan="1" colspan="1">1.99</td><td align="center" rowspan="1" colspan="1">3.98E-05</td></tr><tr><td rowspan="1" colspan="1">MCF2L</td><td rowspan="1" colspan="1">MCF.2 cell line derived transforming sequence-like</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">4.17E-05</td></tr><tr><td rowspan="1" colspan="1">MMP11</td><td rowspan="1" colspan="1">matrix metallopeptidase 11 (stromelysin 3)</td><td align="center" rowspan="1" colspan="1">1.67</td><td align="center" rowspan="1" colspan="1">5.01E-12</td></tr><tr><td rowspan="1" colspan="1">NFATC1</td><td rowspan="1" colspan="1">nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent
1</td><td align="center" rowspan="1" colspan="1">1.61</td><td align="center" rowspan="1" colspan="1">6.46E-05</td></tr><tr><td rowspan="1" colspan="1">NUTM2F/NUTM2G</td><td rowspan="1" colspan="1">NUT family member 2G</td><td align="center" rowspan="1" colspan="1">1.89</td><td align="center" rowspan="1" colspan="1">3.16E-11</td></tr><tr><td rowspan="1" colspan="1">PHAX</td><td rowspan="1" colspan="1">phosphorylated adaptor for RNA export</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">2.45E-05</td></tr><tr><td rowspan="1" colspan="1">PYCR1</td><td rowspan="1" colspan="1">pyrroline-5-carboxylate reductase 1</td><td align="center" rowspan="1" colspan="1">1.75</td><td align="center" rowspan="1" colspan="1">5.89E-06</td></tr><tr><td rowspan="1" colspan="1">RIN1</td><td rowspan="1" colspan="1">Ras and Rab interactor 1</td><td align="center" rowspan="1" colspan="1">1.78</td><td align="center" rowspan="1" colspan="1">7.94E-05</td></tr><tr><td rowspan="1" colspan="1">SLC24A6</td><td rowspan="1" colspan="1">solute carrier family 24 (sodium/lithium/calcium exchanger), member
6</td><td align="center" rowspan="1" colspan="1">0.45</td><td align="center" rowspan="1" colspan="1">1.20E-04</td></tr><tr><td rowspan="1" colspan="1">SYT17</td><td rowspan="1" colspan="1">synaptotagmin XVII</td><td align="center" rowspan="1" colspan="1">0.57</td><td align="center" rowspan="1" colspan="1">3.98E-14</td></tr><tr><td rowspan="1" colspan="1">TACC2</td><td rowspan="1" colspan="1">transforming, acidic coiled-coil containing protein 2</td><td align="center" rowspan="1" colspan="1">0.57</td><td align="center" rowspan="1" colspan="1">3.16E-18</td></tr><tr><td rowspan="1" colspan="1">TMEM259</td><td rowspan="1" colspan="1">transmembrane protein 259</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">7.41E-06</td></tr><tr><td rowspan="1" colspan="1">TUBG1</td><td rowspan="1" colspan="1">tubulin, gamma 1</td><td align="center" rowspan="1" colspan="1">1.79</td><td align="center" rowspan="1" colspan="1">8.71E-05</td></tr><tr><td rowspan="1" colspan="1">VGLL1</td><td rowspan="1" colspan="1">vestigial like 1 (Drosophila)</td><td align="center" rowspan="1" colspan="1">1.90</td><td align="center" rowspan="1" colspan="1">1.74E-06</td></tr><tr><td rowspan="1" colspan="1">WIZ</td><td rowspan="1" colspan="1">widely interspaced zinc finger motifs</td><td align="center" rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">1.48E-07</td></tr><tr><td rowspan="1" colspan="1">WNK2</td><td rowspan="1" colspan="1">WNK lysine deficient protein kinase 2</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">3.98E-31</td></tr><tr><td rowspan="1" colspan="1">XYLT2</td><td rowspan="1" colspan="1">xylosyltransferase II</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">1.05E-04</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">ZNF528</td><td rowspan="1" colspan="1">zinc finger protein 528</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">8.51E-05</td></tr></tbody></table><table-wrap-foot><fn id="TFN06"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Post-CPB gene expression in patients with POAF+NCD compared with POAF+NORM -
complete list.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid; border-bottom-width:medium;border-top-style:solid; border-top-width:medium"><th align="left" rowspan="1" colspan="1">Accession ID</th><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="center" rowspan="1" colspan="1">FC</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ANKMY2</td><td rowspan="1" colspan="1">ankyrin repeat and MYND domain containing 2</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">1.58E-12</td></tr><tr><td rowspan="1" colspan="1">ANKRD6</td><td rowspan="1" colspan="1">ankyrin repeat domain 6</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">1.38E-08</td></tr><tr><td rowspan="1" colspan="1">AP4E1</td><td rowspan="1" colspan="1">adaptor-related protein complex 4, epsilon 1 subunit</td><td align="center" rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">4.68E-05</td></tr><tr><td rowspan="1" colspan="1">BCS1L</td><td rowspan="1" colspan="1">BC1 (ubiquinol-cytochrome c reductase) synthesis-like</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">7.76E-05</td></tr><tr><td rowspan="1" colspan="1">CDS2</td><td rowspan="1" colspan="1">CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2</td><td align="center" rowspan="1" colspan="1">2.03</td><td align="center" rowspan="1" colspan="1">3.09E-09</td></tr><tr><td rowspan="1" colspan="1">CEBPG</td><td rowspan="1" colspan="1">CCAAT/enhancer binding protein (C/EBP), gamma</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">1.26E-05</td></tr><tr><td rowspan="1" colspan="1">CLEC2B</td><td rowspan="1" colspan="1">C-type lectin domain family 2, member B</td><td align="center" rowspan="1" colspan="1">1.97</td><td align="center" rowspan="1" colspan="1">1.70E-06</td></tr><tr><td rowspan="1" colspan="1">DACH1</td><td rowspan="1" colspan="1">dachshund homolog 1 (Drosophila)</td><td align="center" rowspan="1" colspan="1">2.47</td><td align="center" rowspan="1" colspan="1">8.32E-07</td></tr><tr><td rowspan="1" colspan="1">FKBP9</td><td rowspan="1" colspan="1">FK506 binding protein 9, 63 kDa</td><td align="center" rowspan="1" colspan="1">2.38</td><td align="center" rowspan="1" colspan="1">8.32E-05</td></tr><tr><td rowspan="1" colspan="1">GOLT1B</td><td rowspan="1" colspan="1">golgi transport 1B</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">3.98E-13</td></tr><tr><td rowspan="1" colspan="1">GTF2H2</td><td rowspan="1" colspan="1">general transcription factor IIH, polypeptide 2, 44kDa</td><td align="center" rowspan="1" colspan="1">2.54</td><td align="center" rowspan="1" colspan="1">1.35E-06</td></tr><tr><td rowspan="1" colspan="1">HIST2H2BE (includes others)</td><td rowspan="1" colspan="1">histone cluster 2, H2be</td><td align="center" rowspan="1" colspan="1">1.52</td><td align="center" rowspan="1" colspan="1">3.98E-26</td></tr><tr><td rowspan="1" colspan="1">HIVEP2</td><td rowspan="1" colspan="1">human immunodeficiency virus type I enhancer binding protein 2</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">6.03E-05</td></tr><tr><td rowspan="1" colspan="1">KMO</td><td rowspan="1" colspan="1">kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">1.00E-31</td></tr><tr><td rowspan="1" colspan="1">LOC100506328</td><td rowspan="1" colspan="1">uncharacterized LOC100506328</td><td align="center" rowspan="1" colspan="1">5.99</td><td align="center" rowspan="1" colspan="1">1.38E-07</td></tr><tr><td rowspan="1" colspan="1">LOC728613</td><td rowspan="1" colspan="1">programmed cell death 6 pseudogene</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">6.92E-05</td></tr><tr><td rowspan="1" colspan="1">MAPK14</td><td rowspan="1" colspan="1">mitogen-activated protein kinase 14</td><td align="center" rowspan="1" colspan="1">1.98</td><td align="center" rowspan="1" colspan="1">6.31E-24</td></tr><tr><td rowspan="1" colspan="1">NEK6</td><td rowspan="1" colspan="1">NIMA-related kinase 6</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">1.58E-21</td></tr><tr><td rowspan="1" colspan="1">PDS5B</td><td rowspan="1" colspan="1">PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae)</td><td align="center" rowspan="1" colspan="1">0.48</td><td align="center" rowspan="1" colspan="1">4.79E-05</td></tr><tr><td rowspan="1" colspan="1">PMM1</td><td rowspan="1" colspan="1">phosphomannomutase 1</td><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">1.66E-05</td></tr><tr><td rowspan="1" colspan="1">PPP2R1B</td><td rowspan="1" colspan="1">protein phosphatase 2, regulatory subunit A, beta</td><td align="center" rowspan="1" colspan="1">1.50</td><td align="center" rowspan="1" colspan="1">1.10E-05</td></tr><tr><td rowspan="1" colspan="1">RIOK1</td><td rowspan="1" colspan="1">RIO kinase 1</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">1.00E-15</td></tr><tr><td rowspan="1" colspan="1">RNF144B</td><td rowspan="1" colspan="1">ring finger protein 144B</td><td align="center" rowspan="1" colspan="1">0.60</td><td align="center" rowspan="1" colspan="1">2.88E-05</td></tr><tr><td rowspan="1" colspan="1">SIVA1</td><td rowspan="1" colspan="1">SIVA1, apoptosis-inducing factor</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">8.71E-08</td></tr><tr><td rowspan="1" colspan="1">SLC27A3</td><td rowspan="1" colspan="1">solute carrier family 27 (fatty acid transporter), member 3</td><td align="center" rowspan="1" colspan="1">0.60</td><td align="center" rowspan="1" colspan="1">1.58E-05</td></tr><tr><td rowspan="1" colspan="1">SLC39A8</td><td rowspan="1" colspan="1">solute carrier family 39 (zinc transporter), member 8</td><td align="center" rowspan="1" colspan="1">1.64</td><td align="center" rowspan="1" colspan="1">2.95E-10</td></tr><tr><td rowspan="1" colspan="1">SULT1B1</td><td rowspan="1" colspan="1">sulfotransferase family, cytosolic, 1B, member 1</td><td align="center" rowspan="1" colspan="1">3.68</td><td align="center" rowspan="1" colspan="1">3.09E-06</td></tr><tr><td rowspan="1" colspan="1">SYNE1</td><td rowspan="1" colspan="1">spectrin repeat containing, nuclear envelope 1</td><td align="center" rowspan="1" colspan="1">2.74</td><td align="center" rowspan="1" colspan="1">1.26E-04</td></tr><tr><td rowspan="1" colspan="1">TIMM23</td><td rowspan="1" colspan="1">translocase of inner mitochondrial membrane 23 homolog (yeast)</td><td align="center" rowspan="1" colspan="1">1.83</td><td align="center" rowspan="1" colspan="1">1.26E-13</td></tr><tr><td rowspan="1" colspan="1">TOR1AIP2</td><td rowspan="1" colspan="1">torsin A interacting protein 2</td><td align="center" rowspan="1" colspan="1">1.55</td><td align="center" rowspan="1" colspan="1">3.98E-22</td></tr><tr><td rowspan="1" colspan="1">TTLL12</td><td rowspan="1" colspan="1">tubulin tyrosine ligase-like family, member 12</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">3.55E-05</td></tr><tr><td rowspan="1" colspan="1">TUBB6</td><td rowspan="1" colspan="1">tubulin, beta 6 class V</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">8.13E-06</td></tr><tr><td rowspan="1" colspan="1">YIPF4</td><td rowspan="1" colspan="1">Yip1 domain family, member 4</td><td align="center" rowspan="1" colspan="1">1.68</td><td align="center" rowspan="1" colspan="1">8.32E-05</td></tr><tr><td rowspan="1" colspan="1">ZCCHC10</td><td rowspan="1" colspan="1">zinc finger, CCHC domain containing 10</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">2.09E-09</td></tr><tr><td rowspan="1" colspan="1">ZDHHC12</td><td rowspan="1" colspan="1">zinc finger, DHHC-type containing 12</td><td align="center" rowspan="1" colspan="1">0.47</td><td align="center" rowspan="1" colspan="1">4.37E-05</td></tr><tr><td rowspan="1" colspan="1">ZNF226</td><td rowspan="1" colspan="1">zinc finger protein 226</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">5.01E-29</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">ZNF350</td><td rowspan="1" colspan="1">zinc finger protein 350</td><td align="center" rowspan="1" colspan="1">1.83</td><td align="center" rowspan="1" colspan="1">7.94E-06</td></tr></tbody></table><table-wrap-foot><fn id="TFN07"><p>FC=fold change</p></fn></table-wrap-foot></table-wrap></floats-group></article>